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Background. The recent ISPOR-SMDM Modeling Good Research Practices Task Force on Modeling 
emphasized the importance of conceptualizing and validating models. We report a new model of chronic 
obstructive pulmonary disease (COPD) that was part of the Galaxy project. It is founded on a conceptual 
model, implemented using a novel linked-equation approach, and internally validated.  
Methods. An expert panel developed a conceptual model including causal relationships between disease 
attributes, progression, and final outcomes. Risk equations describing these relationships were estimated using 
data from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study, 
with costs estimated using data from the TOwards a Revolution in COPD Health (TORCH) study. 
Implementation as a linked-equation model enabled direct estimation of health service costs and quality 
adjusted life-years (QALY) for COPD patients over their lifetimes. Internal validation compared three years of 
predicted cohort experience with ECLIPSE results.  
Results. At three years, the Galaxy COPD model predicted annual exacerbation rate, and annual decline in 
forced expiratory volume in one second, all fell within the ECLIPSE data confidence limits, although overall 
survival was outside the observed confidence limits at three years. Projections of the risk equations over time 
permitted extrapolation to patient lifetimes. Averaging the predicted cost and QALY outcomes for the different 
patients within the ECLIPSE cohort gives an estimated lifetime cost of £25,214 (undiscounted)/£20,318 
(discounted) and lifetime QALY of 6.45 (undiscounted/5.24 (discounted) per patient in ECLIPSE.  
Conclusions. A new form of model for COPD was conceptualized, implemented, and internally validated, based 
on a series of linked equations using epidemiological data from ECLIPSE and cost data from TORCH. This 
Galaxy model may predict COPD outcomes from treatment effects on disease attributes such as lung function, 






 Chronic obstructive pulmonary disease (COPD) is a respiratory disorder characterized by airflow 
obstruction, leading to shortness of breath, acute exacerbations, and death [1]. Globally, COPD is the fourth 
leading cause of death [2]. In England, more than 860,000 individuals were diagnosed with COPD in 2009–
2010, corresponding to a prevalence of 1.6% [3]. However, it is estimated that most cases remain undiagnosed 
and that the true prevalence of COPD is much higher, potentially affecting more than 3 million people [1]. 
Smoking is the primary risk factor for developing COPD, and exposure to noxious fumes, dust, and gas are also 
risk factors [4]. The economic burden of COPD is high; it is one of the most costly inpatient conditions treated 
by the National Health Service in the United Kingdom, with an estimated direct cost of £810–930 million per 
year [1]. 
A number of models of COPD exist, which have been used for economic analysis for Health 
Technology Assessment (HTA). The majority of these are structured around disease ‘states’ that are usually 
defined using threshold values of % predicted forced expiratory volume in one second (FEV1), adjusted for 
patients according to age, gender, and height [5,6]. However, recent prognostic modeling has shown that other 
aspects of the disease, such as symptoms and exercise capacity, are also important factors for survival [7-9], and 
clinical guidelines are beginning to acknowledge the multifaceted nature of COPD [2], such that there is 
inherent heterogeneity in health outcomes for COPD patients that depends on more than just FEV1 [8].  
The Galaxy project was undertaken to develop a new disease/economic model for COPD, accounting 
for recent developments in the understanding of COPD as a multifaceted disease. The aim was to develop a 
model with sufficient flexibility to reflect different patient groups, based on an understanding of relationships 
between disease characteristics, risk factors, biomarkers, and surrogates, on relevant clinical outcomes and 
disease progression over time. This allows for a better capture of the inherent heterogeneity and corresponding 
adjustments made for different COPD patient populations, which facilitates comparisons of disease progression 
between different COPD subgroups. The development of the new Galaxy COPD model has adhered as closely 
as possible to best practice guidelines for medical decision modeling [10], which emphasize the importance of 
conceptual modeling [11]. The modeling and analysis we report in this paper was founded upon a conceptual 
model designed by a panel of experts prior to data analysis [12] and a series of linked risk equations that were 
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developed from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) 
data-set based on the relationships from the conceptual modeling exercise [13]. This paper brings the previous 
work together in a cohesive whole and internally validates the model using the same data that were used to 
generate model parameters. The model will also enable estimation of the cost effectiveness of a wide range of 





The ECLIPSE study was a non-interventional, observational, multicenter, three-year study designed to 
determine mechanisms of disease progression and identify biomarkers that could serve as endpoints to measure 
progression of COPD [14]. This study included 2164 COPD patients, with an average age of 63.4 years, an 
average of 0.9 exacerbations in the year prior to study entry, and baseline % predicted FEV1 of 48.3%. Patients 
for whom full information on baseline characteristics were available (n = 1957) were included in the present 
model. 
The TOwards a Revolution in COPD Health (TORCH) study, was a randomized, double-blind study (n 
= 6112) comparing the effectiveness of salmeterol alone, fluticasone proprionate alone, a combination of 
salmeterol and fluticasone proprionate, and placebo, over a three-year period [15]. At baseline, the average age 
was 65.0 years; patients had an average of 1.0 exacerbation in the year prior to study entry, and baseline % 
predicted FEV1 was 44.1%.  
Patients included in the model had baseline characteristics that were slightly different from the original 
published studies, due to small amounts of missing information in the baseline covariates used in the modeling. 
However, there were no important differences between characteristics of the cohorts analyzed here to the 




The conceptualization of the new model of COPD disease progression was reported separately [12], and led to 
the development of a conceptual model of COPD prognosis. Internal validation of the outputs predicted by the 
model was conducted by comparing them with published estimates of decline in reported lung function 
(measured as FEV1) and exercise capacity (measured as six-minute walking distance [6MWD]) within the 
ECLIPSE dataset. In addition, we compared the predicted exacerbation count, survival, and HRQoL with the 
observed data during each of the three years of ECLIPSE. ECLIPSE data were presented as point estimates with 
associated 95% confidence intervals (CIs) at the relevant time points. Estimated covariance matrices are 
reported in Appendix B (moderate exacerbations, fixed effects [Table A8]; severe exacerbations, fixed effects 
[Table A9]; FEV1, fixed effects [Table A10]; dyspnea, most versus none or several days, fixed effects [Table 
A11]; dyspnea (none vs most or several days), fixed effects [Table A12]; cough and sputum, fixed effects 
[Table A13]; 6MWD, fixed effects [Table A14]; SGRQ, fixed effects [Table A15]; mortality, fixed effects 
[Table A16]; survival, fixed effects [Table A17]; probability of hospitalization [Table A18]; ward days [Table 
A19]; intensive care unit [Table A20]; emergency room visits [Table A21]; days and nights at home [Table 
A22]; office visits [Table A13]; outpatient visits [Table A24]). 
.  
 
Structure of the model 
The model described the important prognostic factors for COPD disease progression at baseline; the 
disease progression attributes that evolve over the lifetime of the model, such as exacerbations, lung function, 
exercise capacity, and symptoms; and the final outcomes of mortality, health-related quality of life (HRQoL), 
and health service resource use. In particular, lung function and exacerbations were assumed to affect each other 
in the conceptual model, with lung function affecting symptoms, symptoms affecting exacerbations and all three 
of these attributes affecting exercise capacity [12]. These relationships from the final conceptual model 
development were used as the basis for estimating a series of linked statistical equations based on data from 
ECLIPSE, which formed the epidemiological foundation of the disease model [13].  
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The statistical equations were brought together to estimate the course of COPD for a patient cohort in 
terms of the disease progression attributes defined in the conceptual model, through to final health outcomes of 
(quality adjusted) life expectancy, and health service cost. Observational data from ECLIPSE were used to 
estimate associations between disease progression attributes, together with mortality and HRQoL (measured by 
the St George’s Respiratory Questionnaire for COPD [SGRQ-C]) [16], while adjusting for prognostic baseline 
covariates. However, because ECLIPSE did not record health service resource use, the resource use equations 
were estimated using data from TORCH. 
Figure 1a illustrates the links between the statistical risk equations from the baseline prognostic 
variables through to the disease progression attributes of COPD [13] representing the relationships described in 
the conceptual model [12] above. Figure 1b shows the associations from the baseline covariates and the disease 
progression attributes through to the final health outcomes.  
The Galaxy COPD model starts with the baseline covariates recorded in ECLIPSE (Appendix Table 
A1) and then builds on these by predicting how the baseline covariates affect the disease progression attributes 
of exacerbations, lung function, exercise capacity, and symptoms).  Not all baseline variables were used in every 
equation, though all variables from Table A1 appeared in at least one of the equations. The baseline variables 
and longitudinal disease progression attributes are then used together to predict the final health outcomes of 
HRQoL/utility, survival, and health service resource use and cost over lifetime. 
 
Health service resource use and cost. Compared with previously reported statistical analyses [13], the model 
represented in Figures 1a and 1b includes health service resource use added to the list of final health outcomes. 
COPD-related health service resource use was based on an analysis of the TORCH data from the following 
health service resource use categories: hospital bed days (general ward, intensive care unit), emergency room 
visits, and outpatient visits (hospital, physician office, home day/night). Negative binomial count data models 
with a log link were used for the resource counts, adjusted for the baseline variables from the TORCH study, 
and are reported in full in Appendix A. Indicator variables for the treatment arm of the TORCH study were not 
used, so the intercept of the models (along with the rest of the coefficients) effectively represents a pooling 
across all treatment arms of TORCH. 
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Weighting-predicted health service resource use in each category computed using the relevant United 
Kingdom unit costs for that category [17-19] enabled the annual health service costs associated with the 
progression of COPD to be calculated, taking into account the baseline factors as well as the central disease 
attributes on costs. These costs were then discounted at an annual rate of 3.5% [20] to provide the net present 
value of COPD costs, predicted over the lifetime of each patient who enters the model. 
 
Mapping SGRQ score to EuroQol-5 dimension (EQ-5D) utility. The previously reported statistical 
equations predict the patient-reported outcome of SGRQ-C, as collected in ECLIPSE [13]. However, for health 
economic modeling, a cardinal utility measure of HRQoL, such as the EQ-5D, is required as a basis for 
estimating quality-adjusted life years (QALYs). This was achieved firstly by converting SGRQ-C score to 
SGRQ Total score, as described previously [13], based on guidance from the user manual [15]. A mapping 
function, estimated from data available in TORCH where both instruments had been collected, suggested the 
following relationship between EQ-5D and SGRQ Total score [21]: 
EQ-5D = 0.9617 - 0.0013×SGRQ - 0.0001×SGRQ2 + 0.0231×male 
 The longitudinal survival, lung function, exacerbations, symptoms and exercise capacity equations 
included a time trend term in the regression models [13]. These equations were projected from the observed 
three years of the ECLIPSE study to estimate lifetime outcomes. Weighting-predicted survival each year by 
predicted EQ-5D gave a yearly estimate of quality-adjusted survival. Summing this over the lifetime of the 
model, and applying a discount rate of 3.5% [20] gave the net present value of estimated QALYs over the 
lifetime of each patient entering the model. 
 
Cohort estimation and baseline values 
In order to generate predicted values for the ECLIPSE cohort (employing the statistical equations 
reported previously [13] and the resource use equations described above and reported in the Appendix) the 
baseline characteristics of each of the 1957 patients forming the estimation sample of ECLIPSE were entered 
into the model. Not all equations include all baseline characteristics as covariates, but the set of baseline 
characteristics reported indicate that they were important predictors of outcome in at least one of the statistical 
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equations (see [13] for full details). The resulting predictions of lifetime health service resource use cost and 
QALYs for each patient were estimated based on the predicted symptoms, exacerbations, lung function, and 
exercise capacity as presented in Figures 1A and B. The distribution of costs and QALYs gave an indication of 
the heterogeneity of outcomes predicted by the model, for cohort members with different characteristics. 
Averaging these estimates gave the predicted average lifetime costs and QALYs for the entire ECLIPSE cohort. 
There has been much interest in the role of past exacerbations as a predictor of future exacerbations [22]. 
Therefore the importance of exacerbation history in the model is also explored as a prognostic variable. 
Probabilistic sensitivity analysis 
Uncertainty in each of the statistical model equations was represented through the variance covariance 
matrix of the estimated statistical model. This represents not only the variance of the estimated coefficients, but 
also their covariance, allowing the probabilistic sensitivity analysis to account for both the parameter 
uncertainty, and the potential correlation between input parameters. The method of Cholesky decomposition 
[23] was employed to correlate draws from a multivariate normal distribution of parameter values within each 
equation. This uncertainty was propagated through the model structure, in order to estimate the uncertainty 
associated with the lifetime cost and QALY predictions of the model. This estimation of uncertainty is 
conditional on the individual characteristics of the patient and provides a patient-characteristic specific estimate 
of uncertainty in the predictions of the model. Heterogeneity is represented by the differing predictions for 
patients with different characteristics, while uncertainty is estimated given a set of patient characteristics. 








Validating model projections at three years  
Table 1 shows the predicted results for each of the three years of the model, for overall survival, 
disease progression attributes, and HRQoL. Figure 5a compares the predicted and observed survival for the 
three years of ECLIPSE. For FEV1, the estimated annual decline based on the ECLIPSE study has previously 
been reported as 33mL (95% CI: 29, 37) [24]. This is a relatively good fit with the estimated 27mL annual 
decline estimated using the statistical equations that control for changes in other predictors of the disease 
progression attributes [13], which becomes a 39mL decline once the effects of moderate and severe 
exacerbations on FEV1 are taken into account. Figure 5 also shows the observed and predicted values of % 
predicted FEV1, moderate and severe exacerbations, symptoms, and HRQoL as measured by SGRQ Total score 
over the first three years of the model. The annual rate of total and severe exacerbations in the first year was 
previously reported as 1.21 and 0.22, respectively (CI not reported) [22]. This is comparable with 1.20 and 0.21 
total and severe exacerbations per patient as predicted by the model. The annual decline in 6MWD for ECLIPSE 
patients was previously reported as 5.7m (CIs not reported) [25]. This is comparable with the 7.8m decline 
estimated using the statistical equation [13], which becomes 6.1m when the effects of lung function, 
exacerbations and symptoms over time are taken into account. The predicted SGRQ-C values were significantly 
different from the observed values in years 2 and 3. In general terms, the predictions of lung function and severe 
exacerbations were closer to the reported values for ECLIPSE than the predicted values for moderate 
exacerbations, symptoms, mortality, and quality of life. 
 
Heterogeneity of costs and QALYs 
Averaging over the predicted cost and QALY outcomes for the different patients within the ECLIPSE 
cohort gives an estimated lifetime cost of £25,214 (undiscounted) and £20,318 (discounted) and lifetime QALY 
of 6.45 (undiscounted) and 5.24 (discounted) per patient in the ECLIPSE cohort. As described above, results 
from the model predictions are individualized based on the characteristics of the patient. However, the average 
per-patient lifetime costs and QALYs presented above mask the differences in the individual patient predictions. 
Figure 2 shows the joint distribution of predicted lifetime costs and QALYs for the 1957 patients from 
ECLIPSE, based on the data for those patients with a full dataset available at baseline. In addition to the joint 
distribution on the cost-effectiveness plane, the univariate distributions for lifetime cost and QALYs are shown. 
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As is commonly observed in practice, both health outcomes and costs are predicted to be positively skewed 
across patients.. The correlation between predicted cost and QALY outcomes was modest, with an estimated 
correlation coefficient of 0.08, reflecting the competing influences that patients who live longer generally incur 
more costs, but that those with shorter survival are generally in more advanced stages of disease and cost more. 
 
Lifetime projections by history of exacerbation 
  Figure 3 shows the projected survival (undiscounted, Figure 3a) and total accumulated cost 
(discounted, Figure 3b) for an average patient in ECLIPSE within two subgroups: those with no history of 
exacerbation at study entry, and those with a history of exacerbation at study entry. It is clear from the two 
panels of Figure 3 that history of exacerbation is associated with lower survival and increased cost over the 
lifetime of the patient.  
 
Analysis of uncertainty 
A probabilistic sensitivity analysis was employed to explore the uncertainty in lifetime costs and 
QALYs for two types of patient based on ECLIPSE equations: those with no history of exacerbation at study 
entry, and those with a history of exacerbation at study entry. These results are presented on the cost-
effectiveness plane in Figure 4. Summary results of the uncertainty analysis reveal uncertainty in estimates for 
these two patient subgroups: the additional QALYs was 0.48 for the no-exacerbation history group (95% CI: –







We have presented a new model of COPD that was constructed from an initial conceptualization of the 
disease, and validated using the data source that was used to estimate model parameters. To date, most other 
models have employed state transition models based on % predicted FEV1 as a measure of disease progression. 
In the present analysis, we have broadened the definition of COPD progression to incorporate exacerbations, 
lung function, exercise capacity, and symptoms as central attributes of the condition. This approach is consistent 
with a more contemporary definition of disease severity based on the multifactorial understanding of COPD [7-
9]. Although all previous models have incorporated exacerbations they have tended to do so based on the 
consideration that this is a state that is dependent only on % predicted FEV, and without estimating the 
relationship between exacerbations and disease progression. One exception is the Dutch population model of 
COPD, where each exacerbation causes the FEV1% predicted to decline with 0.19% (95% CI: 0.092, 0.29) [26]. 
The implementation of the model is also novel. The use of a linked equations approach is not 
commonly used in HTA modeling, though it has clear links to the epidemiological literature of causal modeling. 
The approach was made possible through the existence of the ECLIPSE study, which provided a rich source of 
data from which to estimate the interconnected relationships that defined our conceptual model. Furthermore, 
we were able to show that the model was able to predict back the outcomes of the ECLIPSE study – although 
the less than perfect fit in some cases was due to the fact that the structure imposed by the conceptual model 
required all equations to be fit in a particular way, with particular interdependencies. For example, the 
conceptual model suggested that exacerbation history was expected to impact lung function [12], while lung 
function was expected to in turn impact the chance of exacerbation, and the empirical results confirmed this to 
be the case [13]. The resulting model estimated both jointly, adding structure to the analysis. An unrestricted 
prediction model of each outcome independently without representing those interdependencies would 
undoubtedly have provided a better fit to the data, but would have lost the richness of the interdependencies the 
current model is able to estimate. It is these interdependencies that allow the estimation of the impact of 
treatment that is shown to affect a surrogate endpoint (e.g., symptoms and/or FEV1% predicted) on final 
outcomes. 
ECLIPSE was an observational study, designed to gain a better understanding of COPD as a disease. 
This made it ideal in many respects for developing a new model of COPD disease progression. The purpose of 
developing the present model was to provide a method for estimating long-term treatment effects where new 
and existing treatments for COPD are observed to impact on a variety of prognostic markers. We anticipate that 
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the model is most likely to be used when treatment is shown to impact a combination of the disease progression 
attributes of exacerbations, lung function, exercise capacity, or symptoms. 
One of the features of the Galaxy COPD model is the way in which it estimates patient-characteristic 
specific uncertainty in a manner that captures uncertainty in prognosis for individual patients with different 
characteristics. In this way, the model is able to represent uncertainty in the predicted costs and QALY 
outcomes based on the estimated parameters, which include parameters describing heterogeneity between 
individuals. The uncertainty analysis is therefore nested within the analysis of heterogeneity with the 
consequence that while uncertainty can be quantified for individual patient predictions (or equivalently for 
homogeneous cohorts) it is not clear how uncertainty can be represented in the mean outcomes of heterogeneous 
cohorts. 
The strengths of our approach include explicit documenting of an underlying conceptual model, and 
validation of the model constructed according to best practice guidelines [10,11,27]. Furthermore, the model 
incorporates not only the effect of lung function, but also exacerbations, exercise capacity, and symptoms. 
When combined with baseline prognostic variables, this results in a highly flexible model that can generate 
predicted changes in QALYs and health service resource costs associated with a wide variety of potential 
treatments or disease management strategies for COPD, as well as explore potential subgroup analyses. 
Treatment effects can be incorporated into the model in two ways. Firstly, if there is evidence of the treatment 
effect on a given surrogate endpoint included in the model, the effect of changes to this endpoint on the final 
cost, survival, and HRQoL (QALY) outcomes can be estimated. Secondly, if direct evidence of the treatment 
effect on both surrogate and final outcomes is available, then the model can estimate the central association 
corrected treatment effect that acts independently of the central associations. 
Nevertheless, there are limitations to the modeling approach adopted. Firstly, the model is based on a 
single, albeit large, cohort study of COPD, and therefore the generalizability of the model is dependent on the 
generalizability of the ECLIPSE study cohort. The linked equations approach to modeling is likely to be 
unfamiliar to many potential users of the model and this may limit its acceptance by decision makers. For this 
reason, an extensive validation of the model predictions is required. An internal validation against the ECLIPSE 
data was presented, and revealed that in seeking to predict a number of different outcomes simultaneously, the 
fit achieved was not as good as if a single model had been used to fit each of these outcomes independently. 
Nevertheless, the ability of a model to fit the data used to estimate its parameters is a necessary, but not 
14 
sufficient, condition for validation. In practice, external validation (i.e., the ability of the model to predict data 
not used in its construction) is much more important than internal validation. In the next paper of the series, we 
will report the ability of the model to predict outcomes in two large clinical trials that included COPD patients: 
the TORCH study [15] and the Understanding Potential Long-term Impacts on Function with Tiotropium 




We have reported the conceptualization, implementation, and internal validation of a new form of 
model for COPD that is based on a series of linked equations estimated from a longitudinal cohort study of 
COPD patients. This Galaxy COPD model is capable of predicting COPD outcomes for a variety of potential 
treatment effects on intermediate risk factors in both the short and long term. Further external validation of 
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Table 1 Model Predictions Over the 3-Year Timeframe of ECLIPSE 
 Baseline Year 1 Year 2 Year 3 
Individual simulations 

















FEV1 % predicted, % 48.1 
 (47.4, 48.8) 
15.6 47.0 
 (46.3, 47.7) 
15.5 46.1 
 (45.4, 46.8) 
15.3 45.2 
 (44.5, 45.8) 
15.2 









Total exacerbations in  
previous 12 months 






















Dyspnea symptoms                 


















None, % 6.6   6.5   6.4   6.3   
Cough and sputum                 









Without criteria,† % 51.7   52.5   53.1   53.8   


















6MWD, six-minute walk distance; FEV1, forced expiratory volume in one second; SD, standard deviation; SGRQ-C, St. George’s Respiratory Questionnaire for COPD. 
*With criteria: cough and/or sputum most days per week; †Without criteria: cough and/or sputum not at all or several days per week  
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Figure 1. Linking baseline prognostic variables, through disease progression attributes, to final COPD 
outcomes. Panel (a) shows the relationship between the central attributes in the different time periods. Panel (b) 







The associations between disease progression attributes shown in Figure 1a are omitted to aid clarity of 
presentation. COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; BMI, body mass 
index; mMRC, modified Medical Research Council questionnaire; SGRQ, St George’s Respiratory 
Questionnaire score; 6MWD, six-minute walking distance; BC, baseline covariates; FEV1, forced expiratory 
volume in one second; RU, resource utilization; t, time; QALY, quality-adjusted life years. *FEV1 (mL) was 
calculated using the risk equation at year ‘t’ and converted to FEV1 % predicted based on the cohort profile.   
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Figure 2. Joint distribution of predicted lifetime costs and QALYs for individual patients on the cost-
effectiveness plane together with histograms of the cost and QALY histograms showing heterogeneity across the 
1957 patients with complete data in ECLIPSE.  






Figure 3. Lifetime projections for ECLIPSE cohort of (a) survival and (b) cumulative costs for patients with and 







Figure 4. Illustration of probabilistic uncertainty for ECLIPSE subgroups on the cost-effectiveness plane for (a) 
patients with no history of exacerbation and (b) patients with a history of exacerbations.  
 
QALY, quality-adjusted life years.
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Figure 5. Observed versus predicted outcomes from ECLIPSE over three years for (a) survival (b) % predicted 
FEV1 (c) moderate and severe exacerbations (d) dyspnea symptoms (e) cough and/or sputum symptoms and (f) 
SGRQ-C score. 
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Table A1 Baseline Patient Characteristics for ECLIPSE and TORCH 
 ECLIPSE 
(n = 1957) 
TORCH (Pooled All Arms) 
(n = 6108) 
Baseline characteristics   
Mean age (SD), yrs 63.4 (7.1) 65.0 (8.3) 
Gender (male), %  65.5 76.0 
Mean height (SD), cm 169.4 (8.8)  168.7 (8.8)  
Body mass index, %   
Low ≤20 kg/m2 14.7 13.0 
Med >20 – ≤ 30 kg/m2 63.1 70.0 
High >30 kg/m2 22.3 17.0 
Current smokers, %  36.6 43.0 
29 
CVD comorbidity, % 32.9 22.0 
‘Other’ comorbidity,* % 73.3 79.0 
≥1 exacerbation in prior year, % 47.1 57.0 
Mean exacerbations in prior year (SD) 0.78 (0.88) 0.89 (0.86) 
Mean fibrinogen (SD), mcg/mL 460.5 (104.8) – 
mMRC score, %   
0 12.7 7.0 
1 34.0 42.5 
≥2 53.2 50.5 
  
30 


































95% CI 26.7, 30.7 44.0, 46.0 
































95% CI 47.4, 48.8 48.8, 49.8 
SD, standard deviation; 6MWD, six-minute walking distance; CI, confidence interval; CVD, cardiovascular disease; FEV1, forced expiratory volume in one second; mMRC, 
modified Medical Research Council questionnaire; SD, standard deviation; SGRQ-C, St George’s Respiratory Questionnaire for COPD. *‘Other’ comorbidity includes any 
reported non-CVD comorbidity.
33 
APPENDIX A TORCH Resource Utilization Risk Equations 
Table A2 Resource Utilization – Ward Days (excluding ICU wards) 
Explanatory Variable Effect 95% Confidence Intervals P Value 
Lower Upper 
Intercept –1.0688 –1.7276 –0.4101 0.0015 
Time, years 0.1103 0.0369 0.1836 0.0032 
Recent moderate exacerbations –0.0781 –0.0939 –0.0624 <0.0001 
Recent severe exacerbations 0.4721 0.4518 0.4925 <0.0001 
FEV1 % predicted (lagged 12 months) –0.0149 –0.0190 –0.0108 <0.0001 
Dyspnea symptom (lagged 12 months) - most days 
versus none 
0.2125 –0.0232 0.4482 0.0773 
Dyspnea symptom (lagged 12 months) - several 
days versus none  
0.2679 0.0388 0.4969 0.0219 
Cough and sputum (lagged 12 months) 0.1864 0.0660 0.3067 0.0024 
Age, years 0.0105 0.0032 0.0178 0.0051 
CVD comorbidity (yes versus no)  0.0269 –0.0996 0.1535 0.6768 
Other comorbidity (yes versus no)* –0.1690 –0.3047 –0.0334 0.0146 
Smoking status (current versus former) –0.1992 –0.3185 –0.0799 0.0011 
Gender (female versus male)  –0.1495 –0.2951 –0.0039 0.0442 
34 
BMI (high versus normal)  –0.3781 –0.5557 –0.2005 <0.0001 
BMI (low versus normal)  0.2960 0.1678 0.4241 <0.0001 
Baseline mMRC (mMRC ≥2) –0.0046 –0.2553 0.2461 0.9715 
Baseline SGRQ 0.0147 0.0109 0.0185 <0.0001 
Prior exacerbations (≥1 versus 0) 0.4613 0.3383 0.5843 <0.0001 
Number of patients=4669 
Number of observations=11,463 
    
AIC=63,631.99     
AIC, Akaike information criterion; BMI, body-mass index; CVD, cardiovascular disease; FEV1, forced 
expiratory volume in one second; ICU, intensive care unit; mMRC, modified Medical Research Council score; 
SGRQ, St George’s respiratory questionnaire. *Other, any reported non-CVD comorbidity. Bold = P < 0.05.   
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Table A3 Resource Utilization – ICU Days 
Explanatory Variable Effect 95% Confidence Intervals P Value 
Lower Upper 
Intercept –2.1133 –4.2101 –0.0166 0.0482 
Time, years 0.5465 0.2952 0.7979 <0.0001 
Recent moderate exacerbations 0.0245 –0.0161 0.0650 0.2371 
Recent severe exacerbations 0.4223 0.3608 0.4838 <0.0001 
FEV1 % predicted (lagged 12 months) –0.0238 –0.0377 –0.0100 0.0007 
Dyspnea symptoms (lagged 12 months) - most 
days versus none 
–0.5286 –1.2178 0.1607 0.1328 
Dyspnea symptoms (lagged 12 months) - several 
days versus none  
–0.0624 –0.6960 0.5712 0.8470 
Cough and sputum (lagged 12 months) –0.0344 –0.4437 0.3750 0.8693 
Age, years –0.0029 –0.0275 0.0216 0.8153 
CVD comorbidity (yes versus no)  0.6546 0.2688 1.0404 0.0009 
Other comorbidity (yes versus no)* 0.3295 –0.1954 0.8544 0.2186 
Smoking status (current versus former) 0.3026 –0.0922 0.6974 0.1330 
Gender (female versus male)  –0.9816 –1.5658 –0.3974 0.0010 
BMI (high versus normal)  0.0403 –0.4761 0.5567 0.8784 
36 
BMI (low versus normal)  0.2310 –0.2199 0.6819 0.3154 
Baseline mMRC (mMRC ≥2) –0.7611 –1.3680 –0.1543 0.0140 
Baseline SGRQ 0.0142 0.0015 0.0268 0.0282 
Prior exacerbations (≥1 versus 0) –0.0076 –0.3889 0.3737 0.9688 
Number of patients=4669 
Number of observations=11,463 
    
AIC=10,959.29     
AIC, Akaike Information Criterion; BMI, body-mass index; CVD, cardiovascular disease; FEV1, forced 
expiratory volume in one second; ICU, intensive care unit; mMRC, modified Medical Research Council score; 
SGRQ, St George’s Respiratory Questionnaire. *Other, any reported non-CVD comorbidity. Bold = P < 0.05.   
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Table A4 Resource Utilization – Emergency Room Visits  
Explanatory Variable Effect 95% Confidence Intervals P Value 
Lower Upper 
Intercept –2.3762 –4.2039 –0.5485 0.0108 
Time, years –0.087 –0.2969 0.1229 0.4168 
Recent moderate exacerbations 0.076 0.0427 0.1093 <0.0001 
Recent severe exacerbations 0.2387 0.1736 0.3038 <0.0001 
FEV1 % predicted (lagged 12 months) –0.0200 –0.0319 –0.0082 0.0002 
Dyspnea symptoms (lagged 12 months) - most 
days versus none 
0.1244 –0.5732 0.8219 0.7268 
Dyspnea symptoms (lagged 12 months) - several 
days versus none 
0.1653 –0.4980 0.8286 0.6252 
Cough and sputum (lagged 12 months) –0.0627 –0.4055 0.2801 0.7200 
Age, years 0.0157 –0.0056 0.0370 0.1489 
CVD comorbidity (yes versus no)  –0.1036 –0.4877 0.2806 0.5973 
Other comorbidity (yes versus no)* –0.2442 –0.6403 0.1520 0.2270 
Smoking status (current versus former) –0.1766 –0.5235 0.1703 0.3185 
Gender (female versus male)  –0.4055 –0.8142 0.0032 0.0518 
BMI (high versus normal)  –0.6200 –1.1691 –0.0709 0.0269 
38 
BMI (low versus normal)  0.3220 –0.0449 0.6889 0.0854 
Baseline mMRC (mMRC ≥2) –0.4203 –0.9795 0.1390 0.1408 
Baseline SGRQ 0.0046 –0.0061 0.0152 0.4013 
Prior exacerbations (≥1 versus 0) 0.2226 –0.1104 0.5557 0.1901 
Number of patients=4669 
Number of observations=11,463 
    
AIC=8856.77     
AIC, Akaike information criterion; BMI, body-mass index; CVD, cardiovascular disease; FEV1, forced 
expiratory volume in one second; mMRC, modified Medical Research Council score; SGRQ, St George’s 
respiratory questionnaire. *Other, any reported non-CVD comorbidity. Bold = P < 0.05.  
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Table A5 Resource Utilization – Day and Night Home Visits 
Explanatory Variable Effect 95% Confidence Intervals P Value 
Lower Upper 
Intercept –7.1905 –10.5055 –3.8755 <0.0001 
Time, years –0.3722 –0.7330 –0.0114 0.0432 
Recent moderate exacerbations 0.0243 –0.0452 0.0938 0.4929 
Recent severe exacerbations 0.1544 –0.0022 0.3110 0.0533 
FEV1 % predicted (lagged 12 months) –0.0106 –0.0291 0.0079 0.2603 
Dyspnea symptoms (lagged 12 months) - most 
days versus none 
–0.8936 –1.8308 0.0435 0.0616 
Dyspnea symptoms (lagged 12 months) - several 
days versus none 
–0.3437 –1.1905 0.5031 0.4263 
Cough and sputum (lagged 12 months) –0.0562 –0.6063 0.4940 0.8414 
Age, years 0.0297 –0.0053 0.0648 0.0965 
CVD comorbidity (yes versus no)  0.1027 –0.4805 0.6859 0.7300 
Other comorbidity (yes versus no)* 0.3729 –0.3412 1.0869 0.3061 
Smoking status (current versus former) –0.1645 –0.7229 0.3938 0.5635 
Gender (female versus male)  –0.1454 –0.7972 0.5063 0.6618 
BMI (high versus normal)  –0.7955 –1.7509 0.1599 0.1027 
40 
BMI (low versus normal)  0.2669 –0.3350 0.8687 0.3848 
Baseline mMRC (mMRC ≥2) 0.9875 –0.6672 2.6422 0.2421 
Baseline SGRQ 0.0127 –0.0042 0.0296 0.1417 
Prior Exacerbations (≥1 versus 0) 1.3104 0.6188 2.0019 0.0002 
Number of patients=4669 
Number of observations=11,463 
    
AIC=3025.99     
AIC, Akaike information criterion; BMI, body-mass index; CVD, cardiovascular disease; FEV1, forced 
expiratory volume in one second; mMRC, modified Medical Research Council score; SGRQ, St George’s 
respiratory questionnaire. *Other, any reported non-CVD comorbidity. Bold = P < 0.05. Note: includes day and 
night time home visits by a health care worker. 
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Table A6 Resource Utilization – Outpatient Physician Office Visits 
Explanatory Variable Effect 95% Confidence Intervals P Value 
Lower Upper 
Intercept –0.3691 –1.1591 0.4209 0.3598 
Time, years 0.0531 –0.0369 0.1430 0.2476 
Recent moderate exacerbations 0.1105 0.0981 0.1230 <0.0001 
Recent severe exacerbations 0.0391 –0.0129 0.0912 0.1405 
FEV1 % predicted (lagged 12 months) –0.0108 –0.0158 –0.0058 <0.0001 
Dyspnea symptoms (lagged 12 months) - most 
days versus none 
0.6740 0.3144 1.0335 0.0002 
Dyspnea symptom (lagged 12 months) - several 
days versus none 
0.4651 0.1161 0.8142 0.0090 
Cough and sputum (lagged 12 months) 0.1559 0.0074 0.3044 0.0396 
Age, years –0.0114 –0.0201 –0.0027 0.0100 
CVD comorbidity (yes versus no)  –0.0645 –0.2312 0.1022 0.4480 
Other comorbidity (yes versus no)* 0.0262 –0.1691 0.2214 0.7928 
Smoking status (current versus former) –0.2163 –0.3653 –0.0673 0.0044 
Gender (female versus male)  0.1847 0.0287 0.3407 0.0203 
BMI (high versus normal)  –0.2485 –0.4379 –0.0591 0.0101 
42 
BMI (low versus normal)  –0.2544 –0.4428 –0.0661 0.0081 
Baseline mMRC (mMRC ≥2) –0.1588 –0.4185 0.1009 0.2307 
Baseline SGRQ –0.0016 –0.0063 0.0030 0.4930 
Prior Exacerbations (≥1 versus 0) 0.3351 0.1898 0.4805 <0.0001 
Number of Patients=4669 
Number of Observations=11,463 
    
AIC=25,644.62     
AIC, Akaike information criterion; BMI, body-mass index; CVD, cardiovascular disease; FEV1, forced 
expiratory volume in one second; mMRC, modified Medical Research Council score; SGRQ, St George’s 




Table A7 Resource Utilization – Hospital Outpatient Visits 
Explanatory Variable Effect 95% Confidence Intervals P Value 
Lower Upper 
Intercept –0.9087 –2.1694 0.3519 0.1577 
Time, years –0.1898 –0.3425 –0.0371 0.0148 
Recent moderate exacerbations 0.0844 0.0589 0.1100 <0.0001 
Recent severe exacerbations 0.0406 –0.0485 0.1298 0.3715 
FEV1 % predicted (lagged 12 lonths) –0.0123 –0.0202 –0.0044 0.0023 
Dyspnea symptoms (lagged 12 months) - most 
days versus none 
–0.576 –1.0130 –0.1390 0.0098 
Dyspnea symptoms (lagged 12 months) - several 
days versus none 
–0.1533 –0.5544 0.2479 0.4539 
Cough and sputum (lagged 12 months) 0.1369 –0.1030 0.3768 0.2635 
Age, years –0.0011 –0.0156 0.0134 0.8816 
CVD comorbidity (yes versus no)  0.0388 –0.2226 0.3003 0.7709 
Other comorbidity (yes versus no)* –0.2584 –0.5279 0.0110 0.0601 
Smoking status (current versus former) –0.4398 –0.6877 –0.1918 0.0005 
Gender (female versus male)  –0.6256 –0.9357 –0.3155 <0.0001 
BMI (high versus normal)  –0.6665 –1.0561 –0.2768 0.0008 
44 
BMI (low versus normal)  0.2183 –0.0504 0.4869 0.1113 
Baseline mMRC (mMRC ≥2) 0.0975 –0.3818 0.5769 0.6900 
Baseline SGRQ 0.0140 0.0065 0.0214 0.0002 
Prior Exacerbations (≥1 versus 0) 0.4280 0.1844 0.6717 0.0006 
Number of Patients=4669 
Number of Observations=11463 
    
AIC=22427.22     
AIC, Akaike information criterion; BMI, body-mass index; CVD, cardiovascular disease; FEV1, forced 
expiratory volume in one second; mMRC, modified Medical Research Council score; SGRQ, St George’s 
respiratory questionnaire. *Other, any reported non-CVD comorbidity.  
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APPENDIX B Covariance matrices  
Table A8 Covariance matrix (moderate exacerbations; fixed effects) 










































Intercept  0.0526700 -0.0040100 0.0038690 -0.0000520 -0.0027300 -0.0030180 0.0003053 -0.0003780 0.0004249 -0.0000790 -0.0012830 -0.0008700 -0.0005290 -0.0013160 -0.0000150 -0.0000084 -0.0003970 -0.0000780 -0.0088560 
Study years -0.0040100 0.0018570 -0.0018560 0.0000015 0.0000401 0.0000467 0.0000196 0.0000003 0.0000093 -0.0000032 -0.0000073 -0.0000140 -0.0000029 0.0000240 -0.0000001 0.0000000 0.0000069 0.0000001 0.0038940 
Time*prior exac. 0.0038690 -0.0018560 0.0026590 -0.0000001 0.0000112 -0.0000470 -0.0000240 0.0000004 -0.0000220 0.0000044 0.0000136 0.0000090 -0.0000140 -0.0000370 0.0000000 0.0000000 -0.0000003 -0.0000001 -0.0055300 
Any FEV1 % 
predicted 
-0.0000520 0.0000015 -0.0000001 0.0000014 0.0000121 0.0000059 -0.0000020 -0.0000004 -0.0000031 -0.0000043 -0.0000042 -0.0000091 -0.0000087 0.0000071 0.0000000 0.0000000 0.0000062 0.0000001 0.0000047 
Dyspnea (lagged 12 
months), most days  
-0.0027300 0.0000401 0.0000112 0.0000121 0.0045110 0.0037940 -0.0002440 -0.0000093 -0.0000430 -0.0000560 -0.0000280 -0.0001220 -0.0000540 0.0000276 -0.0000005 0.0000002 -0.0001020 -0.0000160 -0.0000680 
Dyspnea (lagged 12 
months), several 
-0.0030180 0.0000467 -0.0000470 0.0000059 0.0037940 0.0044850 -0.0000570 -0.0000044 -0.0000570 -0.0000720 -0.0000820 -0.0000740 0.0000341 -0.0000100 -0.0000006 0.0000002 -0.0000400 -0.0000080 0.0000150 
Any symptom   0.0003053 0.0000196 -0.0000240 -0.0000020 -0.0002440 -0.0000570 0.0011110 -0.0000018 0.0000188 -0.0000630 -0.0002620 0.0001260 0.0000371 -0.0000330 -0.0000002 -0.0000002 0.0000221 -0.0000055 -0.0000200 
Age -0.0003780 0.0000003 0.0000004 -0.0000004 -0.0000093 -0.0000044 -0.0000018 0.0000060 -0.0000086 -0.0000063 0.0000220 0.0000123 0.0000099 0.0000044 0.0000001 -0.0000001 -0.0000046 0.0000005 0.0000010 
CVD comorbidity 
(yes) 
0.0004249 0.0000093 -0.0000220 -0.0000031 -0.0000430 -0.0000570 0.0000188 -0.0000086 0.0012310 -0.0001450 0.0000133 0.0001986 -0.0000840 -0.0000460 0.0000001 0.0000001 -0.0000190 -0.0000022 0.0000230 
Other comorbidity 
(yes) 
-0.0000790 -0.0000032 0.0000044 -0.0000043 -0.0000560 -0.0000720 -0.0000630 -0.0000063 -0.0001450 0.0014140 0.0000499 -0.0001830 -0.0001230 0.0001169 0.0000001 -0.0000001 -0.0000490 -0.0000025 -0.0000210 
Current smoker -0.0012830 -0.0000073 0.0000136 -0.0000042 -0.0000280 -0.0000820 -0.0002620 0.0000220 0.0000133 0.0000499 0.0012970 0.0000006 0.0001044 -0.0001800 -0.0000002 -0.0000004 0.0000651 -0.0000003 0.0000199 
Female -0.0008700 -0.0000140 0.0000090 -0.0000091 -0.0001220 -0.0000740 0.0001260 0.0000123 0.0001986 -0.0001830 0.0000006 0.0011330 0.0001050 -0.0001530 0.0000008 -0.0000003 -0.0000640 0.0000027 -0.0001030 
High BMI  -0.0005290 -0.0000029 -0.0000140 -0.0000087 -0.0000540 0.0000341 0.0000371 0.0000099 -0.0000840 -0.0001230 0.0001044 0.0001050 0.0016080 0.0002966 0.0000010 -0.0000008 -0.0000350 -0.0000004 0.0000774 
Low BMI  -0.0013160 0.0000240 -0.0000370 0.0000071 0.0000276 -0.0000100 -0.0000330 0.0000044 -0.0000460 0.0001169 -0.0001800 -0.0001530 0.0002966 0.0021680 0.0000002 0.0000007 0.0000760 -0.0000018 0.0000486 
Baseline 6MWD  -0.0000150 -0.0000001 0.0000000 0.0000000 -0.0000005 -0.0000006 -0.0000002 0.0000001 0.0000001 0.0000001 -0.0000002 0.0000008 0.0000010 0.0000002 0.0000000 0.0000000 0.0000012 0.0000000 0.0000000 
Fibrinogen -0.0000084 0.0000000 0.0000000 0.0000000 0.0000002 0.0000002 -0.0000002 -0.0000001 0.0000001 -0.0000001 -0.0000004 -0.0000003 -0.0000008 0.0000007 0.0000000 0.0000000 0.0000000 0.0000000 -0.0000003 
Baseline mMRC -0.0003970 0.0000069 -0.0000003 0.0000062 -0.0001020 -0.0000400 0.0000221 -0.0000046 -0.0000190 -0.0000490 0.0000651 -0.0000640 -0.0000350 0.0000760 0.0000012 0.0000000 0.0014800 -0.0000140 -0.0000420 
Baseline SGRQ -0.0000780 0.0000001 -0.0000001 0.0000001 -0.0000160 -0.0000080 -0.0000055 0.0000005 -0.0000022 -0.0000025 -0.0000003 0.0000027 -0.0000004 -0.0000018 0.0000000 0.0000000 -0.0000140 0.0000012 -0.0000038 
Prior exac. -0.0088560 0.0038940 -0.0055300 0.0000047 -0.0000680 0.0000150 -0.0000200 0.0000010 0.0000230 -0.0000210 0.0000199 -0.0001030 0.0000774 0.0000486 0.0000000 -0.0000003 -0.0000420 -0.0000038 0.0127100 
BMI, body-mass index; CVD, cardiovascular disease; exac., exacerbation; FEV1, forced expiratory volume in one second; mMRC, modified Medical Research Council; SGRQ, St George’s Respiratory Questionnaire; 6MWD, six-minute walk test distance.  
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Table A9 Covariance matrix for (severe exacerbations; fixed effects) 














































Intercept  0.2247400 -0.0175600 0.0168900 -0.0001880 -0.0150100 -0.0161400 0.0010630 -0.0015930 0.0015130 -0.0003440 -0.0053640 -0.0039950 -0.0016840 -0.0047160 -0.0000560 -0.0000310 -0.0020840 -0.0003280 -0.0411900 
Study years -0.0175600 0.0076740 -0.0076680 0.0000068 0.0001416 0.0002067 0.0001327 0.0000001 0.0000169 0.0000033 -0.0000470 -0.0000700 -0.0000620 0.0000609 -0.0000008 -0.0000001 0.0000135 -0.0000004 0.0173800 
Time*prior exac. 0.0168900 -0.0076680 0.0107900 0.0000002 0.0001356 -0.0000910 -0.0002170 0.0000031 -0.0001180 0.0000089 0.0000976 0.0000258 0.0000252 -0.0001210 0.0000004 0.0000003 0.0000092 0.0000005 -0.0239800 
Any FEV1 % 
predicted 
-0.0001880 0.0000068 0.0000002 0.0000067 0.0000526 0.0000280 -0.0000076 -0.0000020 -0.0000170 -0.0000130 -0.0000160 -0.0000450 -0.0000390 0.0000258 -0.0000002 0.0000001 0.0000257 0.0000002 0.0000173 
Dyspnea (lagged 
12 months), most 
days  




-0.0161400 0.0002067 -0.0000910 0.0000280 0.0176500 0.0212800 -0.0001910 -0.0000059 -0.0001190 -0.0004130 -0.0002590 -0.0002110 0.0002245 -0.0003160 -0.0000016 0.0000005 -0.0000840 -0.0000240 0.0000596 
Any symptom   0.0010630 0.0001327 -0.0002170 -0.0000076 -0.0009830 -0.0001910 0.0044290 -0.0000070 -0.0000004 -0.0002240 -0.0010430 0.0004606 0.0000862 -0.0001250 -0.0000007 -0.0000008 0.0000853 -0.0000210 0.0001418 
Age -0.0015930 0.0000001 0.0000031 -0.0000020 -0.0000200 -0.0000059 -0.0000070 0.0000247 -0.0000290 -0.0000250 0.0000844 0.0000578 0.0000327 0.0000207 0.0000002 -0.0000002 -0.0000210 0.0000017 0.0000041 
CVD co-
morbidity (yes) 
0.0015130 0.0000169 -0.0001180 -0.0000170 -0.0001420 -0.0001190 -0.0000004 -0.0000290 0.0043170 -0.0005070 0.0001206 0.0007453 -0.0002300 -0.0001660 0.0000007 0.0000002 -0.0001610 -0.0000083 0.0001474 
Other co-
morbidity (yes) 
-0.0003440 0.0000033 0.0000089 -0.0000130 -0.0002930 -0.0004130 -0.0002240 -0.0000250 -0.0005070 0.0052340 0.0000754 -0.0007720 -0.0005840 0.0003829 0.0000003 0.0000000 -0.0002360 -0.0000080 -0.0000710 
Current smoker -0.0053640 -0.0000470 0.0000976 -0.0000160 -0.0000850 -0.0002590 -0.0010430 0.0000844 0.0001206 0.0000754 0.0048930 0.0000833 0.0004544 -0.0005350 -0.0000004 -0.0000011 0.0003857 -0.0000025 0.0001153 
Female -0.0039950 -0.0000700 0.0000258 -0.0000450 -0.0003720 -0.0002110 0.0004606 0.0000578 0.0007453 -0.0007720 0.0000833 0.0049020 0.0003239 -0.0006610 0.0000032 -0.0000008 -0.0002630 0.0000108 -0.0003600 
High BMI  -0.0016840 -0.0000620 0.0000252 -0.0000390 -0.0000150 0.0002245 0.0000862 0.0000327 -0.0002300 -0.0005840 0.0004544 0.0003239 0.0067820 0.0012630 0.0000032 -0.0000024 -0.0000180 -0.0000033 0.0000671 
Low BMI  -0.0047160 0.0000609 -0.0001210 0.0000258 -0.0001180 -0.0003160 -0.0001250 0.0000207 -0.0001660 0.0003829 -0.0005350 -0.0006610 0.0012630 0.0065920 0.0000003 0.0000026 0.0003608 -0.0000050 0.0000159 
6MWD -0.0000560 -0.0000008 0.0000004 -0.0000002 -0.0000010 -0.0000016 -0.0000007 0.0000002 0.0000007 0.0000003 -0.0000004 0.0000032 0.0000032 0.0000003 0.0000001 0.0000000 0.0000050 0.0000002 -0.0000010 
Fibrinogen -0.0000310 -0.0000001 0.0000003 0.0000001 0.0000004 0.0000005 -0.0000008 -0.0000002 0.0000002 0.0000000 -0.0000011 -0.0000008 -0.0000024 0.0000026 0.0000000 0.0000001 -0.0000001 0.0000000 -0.0000011 
Baseline mMRC -0.0020840 0.0000135 0.0000092 0.0000257 -0.0002710 -0.0000840 0.0000853 -0.0000210 -0.0001610 -0.0002360 0.0003857 -0.0002630 -0.0000180 0.0003608 0.0000050 -0.0000001 0.0061180 -0.0000490 -0.0003410 
Baseline SGRQ -0.0003280 -0.0000004 0.0000005 0.0000002 -0.0000510 -0.0000240 -0.0000210 0.0000017 -0.0000083 -0.0000080 -0.0000025 0.0000108 -0.0000033 -0.0000050 0.0000002 0.0000000 -0.0000490 0.0000046 -0.0000190 
Prior exac. -0.0411900 0.0173800 -0.0239800 0.0000173 -0.0003410 0.0000596 0.0001418 0.0000041 0.0001474 -0.0000710 0.0001153 -0.0003600 0.0000671 0.0000159 -0.0000010 -0.0000011 -0.0003410 -0.0000190 0.0581200 
BMI, body-mass index; CVD, cardiovascular disease; exac., exacerbation; FEV1, forced expiratory volume in one second; mMRC, modified Medical Research Council; SGRQ, St George’s Respiratory Questionnaire; 6MWD, six-minute walk test distance. 
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Table A10 Covariance matrix (FEV1; fixed effects) 



































-7.3696000 -233.19000 -612.36000 -4811.2100 -272.74000 -370.5400 -5.4084000 -3.6456000 -158.77000 -36.9438000 -302.14000 
Study years -21.11170 9.9497000 -9.9098000 0.0059500 -0.5218000 -0.0005000 0.0082350 0.0934100 -0.0206700 20.6269000 -0.1832000 -0.0461500 0.0117100 -0.0013900 0.0010710 0.0684000 0.0021770 0.1704000 
Time*smoker 19.3044000 -9.9098000 28.663300 0.6580000 -0.6502000 0.0050310 0.0166200 -0.0766400 0.0107400 -59.3219000 0.2148000 0.1170000 0.3585000 -0.0011700 -0.0021300 -0.2924000 0.0110700 -0.5572000 
Moderate exac. -8.497100 0.0059500 0.6580000 5.3156000 1.1220000 0.0576000 0.0013130 0.7139000 -0.3620000 -0.5647000 -0.0679800 0.8369000 0.4332000 -0.0007600 -0.0058400 -0.3035000 -0.0404600 -4.2729000 
Severe exac. -3.146700 -0.5218000 -0.6502000 1.1220000 18.069300 0.0582900 -0.0354300 -0.3745000 0.3194000 1.8311000 0.8986000 1.4770000 -1.5820000 0.0037330 -0.0097800 -0.1642000 -0.0959100 -3.4465000 
Height  -364.5300 -0.0005000 0.0050310 0.0576000 0.0582900 1.9854000 0.2632000 0.6210000 0.7577000 0.2111000 23.9684000 -0.3289000 0.7476000 -0.0067900 0.0029780 0.5416000 0.0531900 1.0033000 
Age -195.1300 0.0082350 0.0166200 0.0013130 -0.0354300 0.2632000 2.2090000 -3.3801000 -2.6328000 6.9994000 6.6143000 3.3859000 0.6074000 0.0232600 -0.0181000 -1.1492000 0.1564000 1.1859000 
CVD co-
morbidity (yes) 
-7.369600 0.0934100 -0.0766400 0.7139000 -0.3745000 0.6210000 -3.3801000 451.48000 -71.3392000 -6.4798000 69.2478000 -34.9238000 -0.9924000 0.0606500 0.0219200 -1.0110000 -0.4525000 -2.4974000 
Other co-
morbidity (yes) 





20.6269000 -59.321900 -0.5647000 1.8311000 0.2111000 6.9994000 -6.4798000 4.9674000 565.32000 2.6388000 38.6468000 -79.5795000 -0.0653600 -0.1023000 35.4339000 -0.4423000 19.9507000 
Female -4811.2100 -0.1832000 0.2148000 -0.0679800 0.8986000 23.9684000 6.6143000 69.2478000 -70.9318000 2.6388000 
726.280000
0 
22.7179000 -40.2152000 0.1387000 -0.0626500 8.8505000 1.7299000 -9.9670000 
High BMI  -272.7400 -0.0461500 0.1170000 0.8369000 1.4770000 -0.3289000 3.3859000 -34.9238000 -68.9301000 38.646800 22.7179000 590.97000 126.34000 0.3013000 -0.2722000 -8.1444000 0.0691300 28.2300000 
Low BMI  -370.5400 0.0117100 0.3585000 0.4332000 -1.5820000 0.7476000 0.6074000 -0.9924000 56.6916000 -79.5795000 -40.2152000 126.340000 835.390000 0.0511600 0.2225000 18.8557000 -1.2035000 -25.0944000 
Baseline 6MWD -5.408400 -0.0013900 -0.0011700 -0.0007600 0.0037330 -0.0067900 0.0232600 0.0606500 -0.0112400 -0.0653600 0.1387000 0.3013000 0.0511600 0.0093660 0.0007610 0.4658000 0.0167300 0.0614200 
Fibrinogen -3.645600 0.0010710 -0.0021300 -0.0058400 -0.0097800 0.0029780 -0.0181000 0.0219200 0.0092280 -0.1023000 -0.0626500 -0.2722000 0.2225000 0.0007610 0.0096210 -0.0578000 -0.0049400 -0.1207000 




Baseline SGRQ -36.94380 0.0021770 0.0110700 -0.0404600 -0.0959100 0.0531900 0.1564000 -0.4525000 -1.0762000 -0.4423000 1.7299000 0.0691300 -1.2035000 0.0167300 -0.0049400 -6.1569000 0.3796000 -1.7660000 
Prior exac. -302.1400 0.1704000 -0.5572000 -4.2729000 -3.4465000 1.0033000 1.1859000 -2.4974000 -0.4765000 19.9507000 -9.9670000 28.2300000 -25.0944000 0.0614200 -0.1207000 -23.2089000 -1.7660000 403.290000 
BMI, body-mass index; CVD, cardiovascular disease; mMRC, modified Medical Research Council; SGRQ, St George’s Respiratory Questionnaire; 6MWD, six-minute walk test distance. 
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Table A11 Covariance matrix (dyspnea, most versus none or several days; fixed effects) 

























Intercept 0.7879000 -0.0114100 -0.0008700 -0.0068600 0.0074680 0.0003550 -0.0225400 -0.0149200 -0.0119300 -0.0169600 -0.0002800 -0.0001700 -0.0058500 -0.0015500 -0.0098300 
Study years -0.0114100 0.0043470 0.0000093 0.0000110 -0.0000600 0.0000100 0.0000037 0.0000074 0.0000180 0.0001120 -0.0000012 0.0000009 0.0000490 0.0000140 0.0001260 
FEV1 % 
predicted 
-0.0008700 0.0000093 0.0000230 -0.0000034 -0.0000500 -0.0001000 -0.0000400 -0.0001200 -0.0001200 0.0001110 -0.0000003 0.0000004 0.0000700 -0.0000005 0.0000610 
Age -0.0068600 0.0000110 -0.0000034 0.0001040 -0.0001500 -0.0001200 0.0003240 0.0001930 0.0001840 0.0000030 0.0000012 -0.0000010 -0.0000700 0.0000081 0.0000500 
CVD co-
morbidity (yes) 
0.0074680 -0.0000600 -0.0000500 -0.0001500 0.0214000 -0.0033300 -0.0002500 0.0033350 -0.0012900 -0.0001100 0.0000036 0.0000000 -0.0002100 -0.0000400 -0.0003500 
Other co-
morbidity (yes) 
0.0003550 0.0000100 -0.0001000 -0.0001200 -0.0033300 0.0246400 0.0002980 -0.0034500 -0.0027800 0.0020490 -0.0000005 -0.0000015 -0.0000700 -0.0000400 -0.0002300 
Current smoker -0.0225400 0.0000037 -0.0000400 0.0003240 -0.0002500 0.0002980 0.0209000 0.0001470 0.0023790 -0.0040900 -0.0000014 -0.0000062 0.0013720 -0.0000300 0.0008190 
Female -0.0149200 0.0000074 -0.0001200 0.0001930 0.0033350 -0.0034500 0.0001470 0.0212500 0.0022060 -0.0029400 0.0000110 -0.0000076 -0.0003900 0.0000530 -0.0013100 
High BMI  -0.0119300 0.0000180 -0.0001200 0.0001840 -0.0012900 -0.0027800 0.0023790 0.0022060 0.0282700 0.0052260 0.0000160 -0.0000100 -0.0007400 -0.0000005 0.0012650 
Low BMI  -0.0169600 0.0001120 0.0001110 0.0000030 -0.0001100 0.0020490 -0.0040900 -0.0029400 0.0052260 0.0400600 0.0000003 0.0000150 0.0011020 -0.0000400 -0.0008000 
Baseline 6MWD -0.0002800 -0.0000012 -0.0000003 0.0000012 0.0000036 -0.0000005 -0.0000014 0.0000110 0.0000160 0.0000003 0.0000004 0.0000000 0.0000190 0.0000006 0.0000024 
Fibrinogen -0.0001700 0.0000009 0.0000004 -0.0000010 0.0000000 -0.0000015 -0.0000062 -0.0000076 -0.0000100 0.0000150 0.0000000 0.0000005 0.0000001 -0.0000001 -0.0000050 
mMRC  -0.0058500 0.0000490 0.0000700 -0.0000700 -0.0002100 -0.0000700 0.0013720 -0.0003900 -0.0007400 0.0011020 0.0000190 0.0000001 0.0252500 -0.0002600 -0.0006300 
Baseline SGRQ -0.0015500 0.0000140 -0.0000005 0.0000081 -0.0000400 -0.0000400 -0.0000300 0.0000530 -0.0000005 -0.0000400 0.0000006 -0.0000001 -0.0002600 0.0000230 -0.0000700 
Prior exac. -0.0098300 0.0001260 0.0000610 0.0000500 -0.0003500 -0.0002300 0.0008190 -0.0013100 0.0012650 -0.0008000 0.0000024 -0.0000050 -0.0006300 -0.0000700 0.0189000 





Table A12 Covariance matrix (dyspnea,(none vs most or several days; fixed effects) 
























Intercept 1.5051000 -0.0223400 -0.0021300 -0.0128800 0.0180800 0.0093590 -0.0483000 -0.0240300 -0.0239300 -0.0315700 -0.0005600 -0.0003500 -0.0075100 -0.0027600 -0.0160400 
Study years -0.0223400 0.0089490 0.0000190 0.0000150 0.0000870 -0.0001700 -0.0000300 0.0001750 0.0001920 0.0003180 -0.0000014 0.0000017 0.0001300 0.0000150 0.0002620 
FEV1 % 
predicted 
-0.0021300 0.0000190 0.0000400 -0.0000028 -0.0000700 -0.0001700 -0.0000500 -0.0001700 -0.0001700 0.0001690 -0.0000007 0.0000008 0.0001640 0.0000025 0.0001300 
Age -0.0128800 0.0000150 -0.0000028 0.0001940 -0.0003700 -0.0003000 0.0006460 0.0003000 0.0003570 0.0000170 0.0000026 -0.0000019 -0.0001800 0.0000180 0.0000430 
CVD co-
morbidity (yes) 
0.0180800 0.0000870 -0.0000700 -0.0003700 0.0425400 -0.0074500 -0.0018700 0.0069940 -0.0020000 0.0005560 0.0000050 0.0000003 -0.0008300 -0.0000600 -0.0002900 
Other co-
morbidity (yes) 
0.0093590 -0.0001700 -0.0001700 -0.0003000 -0.0074500 0.0447300 0.0003590 -0.0069100 -0.0062700 0.0049250 0.0000001 -0.0000029 0.0009360 -0.0001400 -0.0006500 
Current smoker -0.0483000 -0.0000300 -0.0000500 0.0006460 -0.0018700 0.0003590 0.0397800 -0.0004200 0.0039290 -0.0083700 -0.0000007 -0.0000089 0.0016810 0.0000110 0.0009710 
Female -0.0240300 0.0001750 -0.0001700 0.0003000 0.0069940 -0.0069100 -0.0004200 0.0398900 0.0043140 -0.0056600 0.0000220 -0.0000200 -0.0004300 0.0000580 -0.0028600 
High BMI  -0.0239300 0.0001920 -0.0001700 0.0003570 -0.0020000 -0.0062700 0.0039290 0.0043140 0.0550300 0.0090430 0.0000350 -0.0000300 -0.0012700 -0.0000200 0.0023230 
Low BMI  -0.0315700 0.0003180 0.0001690 0.0000170 0.0005560 0.0049250 -0.0083700 -0.0056600 0.0090430 0.0906800 -0.0000032 0.0000290 -0.0003200 -0.0000300 -0.0008300 
Baseline 6MWD -0.0005600 -0.0000014 -0.0000007 0.0000026 0.0000050 0.0000001 -0.0000007 0.0000220 0.0000350 -0.0000032 0.0000009 0.0000000 0.0000390 0.0000012 0.0000065 
Fibrinogen -0.0003500 0.0000017 0.0000008 -0.0000019 0.0000003 -0.0000029 -0.0000089 -0.0000200 -0.0000300 0.0000290 0.0000000 0.0000010 -0.0000035 -0.0000001 -0.0000100 
mMRC  -0.0075100 0.0001300 0.0001640 -0.0001800 -0.0008300 0.0009360 0.0016810 -0.0004300 -0.0012700 -0.0003200 0.0000390 -0.0000035 0.0525700 -0.0006000 -0.0006600 
Baseline SGRQ -0.0027600 0.0000150 0.0000025 0.0000180 -0.0000600 -0.0001400 0.0000110 0.0000580 -0.0000200 -0.0000300 0.0000012 -0.0000001 -0.0006000 0.0000430 -0.0001400 
Prior exac. -0.0160400 0.0002620 0.0001300 0.0000430 -0.0002900 -0.0006500 0.0009710 -0.0028600 0.0023230 -0.0008300 0.0000065 -0.0000100 -0.0006600 -0.0001400 0.0371300 




Table A13 Covariance matrix (cough and sputum; fixed effects) 





















Intercept 0.8995000 -0.0106800 -0.0010000 -0.0078700 0.0120800 -0.0027000 -0.0344400 -0.0125300 -0.0115500 -0.0198100 -0.0003200 -0.0001900 -0.0074200 -0.0017500 -0.0113300 
Study years -0.0106800 0.0042290 0.0000180 0.0000051 -0.0000300 -0.0000500 -0.0000600 -0.0000300 -0.0000200 0.0001050 -0.0000013 0.0000009 0.0000310 0.0000038 0.0000800 
FEV1 % 
predicted 
-0.0010000 0.0000180 0.0000230 -0.0000035 -0.0000400 -0.0000900 -0.0000800 -0.0001100 -0.0001200 0.0001210 -0.0000005 0.0000005 0.0000900 0.0000027 0.0000660 
Age -0.0078700 0.0000051 -0.0000035 0.0001190 -0.0002000 -0.0001300 0.0004230 0.0001840 0.0002120 0.0000230 0.0000013 -0.0000011 -0.0000800 0.0000083 0.0000480 
CVD co-
morbidity (yes) 
0.0120800 -0.0000300 -0.0000400 -0.0002000 0.0250500 -0.0042300 -0.0022400 0.0044650 -0.0012700 -0.0005600 0.0000046 -0.0000006 -0.0002800 -0.0000700 -0.0009500 
Other co-
morbidity (yes) 
-0.0027000 -0.0000500 -0.0000900 -0.0001300 -0.0042300 0.0285300 0.0020180 -0.0047100 -0.0039100 0.0027170 -0.0000006 -0.0000001 -0.0003400 -0.0000500 0.0001740 
Current smoker -0.0344400 -0.0000600 -0.0000800 0.0004230 -0.0022400 0.0020180 0.0284200 -0.0020500 0.0012160 -0.0039000 -0.0000045 -0.0000052 0.0019890 0.0000660 0.0021570 
Female -0.0125300 -0.0000300 -0.0001100 0.0001840 0.0044650 -0.0047100 -0.0020500 0.0248200 0.0028160 -0.0035300 0.0000150 -0.0000088 -0.0007000 0.0000072 -0.0021400 
High BMI  -0.0115500 -0.0000200 -0.0001200 0.0002120 -0.0012700 -0.0039100 0.0012160 0.0028160 0.0328700 0.0059290 0.0000200 -0.0000200 -0.0009800 -0.0000300 0.0007520 
Low BMI  -0.0198100 0.0001050 0.0001210 0.0000230 -0.0005600 0.0027170 -0.0039000 -0.0035300 0.0059290 0.0453900 -0.0000011 0.0000160 0.0010590 -0.0000400 -0.0007000 
Baseline 6MWD -0.0003200 -0.0000013 -0.0000005 0.0000013 0.0000046 -0.0000006 -0.0000045 0.0000150 0.0000200 -0.0000011 0.0000005 0.0000000 0.0000230 0.0000008 0.0000014 
Fibrinogen -0.0001900 0.0000009 0.0000005 -0.0000011 -0.0000006 -0.0000001 -0.0000052 -0.0000088 -0.0000200 0.0000160 0.0000000 0.0000005 -0.0000014 -0.0000002 -0.0000045 
mMRC  -0.0074200 0.0000310 0.0000900 -0.0000800 -0.0002800 -0.0003400 0.0019890 -0.0007000 -0.0009800 0.0010590 0.0000230 -0.0000014 0.0299100 -0.0003100 -0.0006000 
Baseline SGRQ -0.0017500 0.0000038 0.0000027 0.0000083 -0.0000700 -0.0000500 0.0000660 0.0000072 -0.0000300 -0.0000400 0.0000008 -0.0000002 -0.0003100 0.0000220 -0.0000700 
Prior exac. -0.0113300 0.0000800 0.0000660 0.0000480 -0.0009500 0.0001740 0.0021570 -0.0021400 0.0007520 -0.0007000 0.0000014 -0.0000045 -0.0006000 -0.0000700 0.0217700 
BMI, body-mass index; CVD, cardiovascular disease; FEV1, forced expiratory volume in one second; mMRC, modified Medical Research Council; SGRQ, St George’s Respiratory Questionnaire; 6MWD, six-minute walk test distance. 
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Table A14 Covariance matrix (6MWD; fixed effects) 













































Intercept  775.57000 -8.1279000 -0.8200000 0.3437000 -1.4927000 -14.07190 -15.073700 1.6746000 -8.0683000 13.1251000 1.8159000 -32.627900 
-
10.1131000 
-0.8853000 -24.723600 -0.1920000 8.7820000 -1.2086000 -7.5818000 
Study years -8.1279000 2.5871000 0.1544000 -0.1592000 0.0211600 0.3901000 0.2552000 0.2683000 0.0050860 0.0218600 -0.1065000 -0.0052400 -0.0765400 0.0233600 0.1484000 0.0007810 0.1915000 0.0035600 0.0071740 
Moderate exac. -0.8200000 0.1544000 1.7882000 0.2656000 0.0142200 -0.1438000 -0.0326500 -0.1156000 -0.0023300 0.1664000 -0.1218000 0.2943000 -0.4142000 0.2204000 0.1569000 -0.0014000 -0.0301800 -0.0071600 -1.3698000 
Severe exac. 0.3437000 -0.1592000 0.2656000 7.1219000 0.0450000 0.2924000 0.1839000 -0.1609000 -0.0242500 -0.1106000 -0.0251800 0.0031960 -0.1446000 0.2738000 -0.3601000 -0.0016500 0.1315000 -0.0270900 -1.0229000 
FEV1 % 
predicted 
-1.4927000 0.0211600 0.0142200 0.0450000 0.0237500 0.1165000 0.0609200 -0.0047300 -0.0021000 -0.0533500 -0.0918200 -0.0432500 -0.1223000 -0.1121000 0.1122000 0.0005130 0.1192000 0.0032210 0.0581000 
Dyspnea (lagged 
12 months), most 
days  




-15.073700 0.2552000 -0.0326500 0.1839000 0.0609200 21.99150 26.5686000 -0.5228000 -0.0741700 -0.2457000 -0.1420000 -0.8161000 -0.7779000 -0.1035000 -0.1144000 0.0026770 -0.0218100 -0.0895000 -0.5971000 
Any symptom   1.6746000 0.2683000 -0.1156000 -0.1609000 -0.0047300 -2.1325000 -0.5228000 12.0476000 -0.0356200 0.1295000 -0.3038000 -3.0651000 1.0620000 0.4315000 -0.0724200 -0.0013800 0.4068000 -0.0535000 -0.4823000 
Age -8.0683000 0.0050860 -0.0023300 -0.0242500 -0.0021000 -0.1107000 -0.0741700 -0.0356200 0.1347000 -0.2215000 -0.2008000 0.4602000 0.2160000 0.1751000 0.0747600 -0.0013800 -0.1400000 0.0079430 0.0537600 
CVD co-
morbidity (yes) 
13.125100 0.0218600 0.1664000 -0.1106000 -0.0533500 -0.0093100 -0.2457000 0.1295000 -0.2215000 29.0187000 -4.4768000 -0.3791000 4.3891000 -1.7880000 -0.5230000 -0.0010500 -0.3387000 -0.0506000 -0.8083000 
Other co-
morbidity (yes) 
1.8159000 -0.1065000 -0.1218000 -0.0251800 -0.0918200 -0.3952000 -0.1420000 -0.3038000 -0.2008000 -4.4768000 32.751400 0.5922000 -4.6456000 -3.9144000 3.1410000 -0.0004900 -0.5080000 -0.0826500 -0.2466000 
Current smoker -32.627900 -0.0052400 0.2943000 0.0031960 -0.0432500 -0.1609000 -0.8161000 -3.0651000 0.4602000 -0.3791000 0.5922000 28.8038000 -0.2382000 2.8981000 -5.0347000 -0.0086900 2.0561000 -0.0119600 0.8870000 
Female -10.113100 -0.0765400 -0.4142000 -0.1446000 -0.1223000 -0.9340000 -0.7779000 1.0620000 0.2160000 4.3891000 -4.6456000 -0.2382000 28.0869000 1.9795000 -3.3595000 -0.0098600 -1.2498000 0.0303500 -1.5562000 
High BMI  -0.8853000 0.0233600 0.2204000 0.2738000 -0.1121000 -0.7825000 -0.1035000 0.4315000 0.1751000 -1.7880000 -3.9144000 2.8981000 1.9795000 36.850400 7.1900000 -0.0215600 -1.9559000 -0.0433500 0.9466000 
Low BMI  -24.72360 0.1484000 0.1569000 -0.3601000 0.1122000 0.0805900 -0.1144000 -0.0724200 0.0747600 -0.5230000 3.1410000 -5.0347000 -3.3595000 7.1900000 54.9424000 0.0185300 1.1167000 -0.0506500 -1.2836000 
Fibrinogen -0.1920000 0.0007810 -0.0014000 -0.0016500 0.0005130 0.0023850 0.0026770 -0.0013800 -0.0013800 -0.0010500 -0.0004900 -0.0086900 -0.0098600 -0.0215600 0.0185300 0.0006140 -0.0041800 -0.0002900 -0.0052300 
Baseline mMRC 8.7820000 0.1915000 -0.0301800 0.1315000 0.1192000 -0.6171000 -0.0218100 0.4068000 -0.1400000 -0.3387000 -0.5080000 2.0561000 -1.2498000 -1.9559000 1.1167000 -0.0041800 34.123300 -0.4139000 -1.0117000 
Baseline SGRQ -1.2086000 0.0035600 -0.0071600 -0.0270900 0.0032210 -0.1662000 -0.0895000 -0.0535000 0.0079430 -0.0506000 -0.0826500 -0.0119600 0.0303500 -0.0433500 -0.0506500 -0.0002900 -0.4139000 0.0242600 -0.1063000 
Prior exac. -7.5818000 0.0071740 -1.3698000 -1.0229000 0.0581000 -0.5665000 -0.5971000 -0.4823000 0.0537600 -0.8083000 -0.2466000 0.8870000 -1.5562000 0.9466000 -1.2836000 -0.0052300 -1.0117000 -0.1063000 26.6820000 
BMI, body-mass index; CVD, cardiovascular disease; FEV1, forced expiratory volume in one second; mMRC, modified Medical Research Council; SGRQ, St George’s Respiratory Questionnaire; 6MWD, six-minute walk test distance. 
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Table A15 Covariance matrix (SGRQ; fixed effects) 

















































Intercept  15.3825000 -0.1509000 -0.0308200 -0.0523300 -0.0018500 -0.0008800 -0.5054000 -0.3500000 0.0164300 -0.1392000 0.1036000 -0.0577600 -0.5141000 -0.5780000 -0.1809000 -0.4960000 -0.0030800 -0.0038600 -0.6183000 -0.3254000 
Study years -0.1509000 0.0470200 0.0030410 -0.0023300 0.0000580 0.0000100 -0.0016200 -0.0010000 0.0003620 0.0003100 0.0003530 -0.0007200 0.0017910 0.0030710 0.0000340 0.0038210 -0.0000600 0.0000190 0.0047310 0.0015730 
Moderate exac. -0.0308200 0.0030410 0.0295400 0.0038390 0.0000076 0.0000095 -0.0059200 -0.0034000 -0.0036900 0.0001800 0.0023250 -0.0030100 0.0053290 -0.0023200 0.0034100 0.0032640 -0.0000100 -0.0000200 -0.0017700 -0.0228200 
Severe exac. -0.0523300 -0.0023300 0.0038390 0.1036000 0.0000930 0.0000160 -0.0041100 0.0015590 0.0034550 0.0002100 -0.0023900 -0.0022900 -0.0007200 0.0089510 0.0074520 -0.0073100 -0.0000300 -0.0000400 -0.0011700 -0.0165800 
6MWD -0.0018500 0.0000580 0.0000076 0.0000930 0.0000071 -0.0000003 0.0001360 0.0000320 0.0000033 0.0000100 0.0000690 0.0000090 0.0001010 -0.0000500 0.0001470 0.0000840 -0.0000044 0.0000003 0.0001740 0.0000680 
FEV1 % 
predicted 
-0.0008800 0.0000100 0.0000095 0.0000160 -0.0000003 0.0000004 0.0000730 0.0000300 -0.0000011 0.0000039 -0.0000200 -0.0000300 -0.0000200 0.0001240 -0.0000700 0.0000670 -0.0000002 0.0000003 0.0000560 0.0000360 
Dyspnea (lagged 
12 months), most 
days  




-0.3500000 -0.0010000 -0.0034000 0.0015590 0.0000320 0.0000300 0.3738000 0.4590000 -0.0110000 0.0000640 -0.0003300 -0.0142700 -0.0086700 0.0102300 -0.0084200 -0.0173700 -0.0000300 -0.0000098 -0.0270000 -0.0082000 
Any symptom   0.0164300 0.0003620 -0.0036900 0.0034550 0.0000033 -0.0000011 -0.0444500 -0.0110000 0.1988000 -0.0005800 0.0074560 -0.0083700 -0.0476100 0.0184900 0.0096160 -0.0059300 0.0000073 -0.0000500 -0.0089200 -0.0108000 
Age -0.1392000 0.0003100 0.0001800 0.0002100 0.0000100 0.0000039 0.0008210 0.0000640 -0.0005800 0.0020440 -0.0033600 -0.0026600 0.0068350 0.0040260 0.0025420 0.0021350 0.0000055 -0.0000100 0.0020590 0.0021180 
CVD co-
morbidity (yes) 
0.1036000 0.0003530 0.0023250 -0.0023900 0.0000690 -0.0000200 0.0021880 -0.0003300 0.0074560 -0.0033600 0.4237000 -0.0671500 -0.0078800 0.0578000 -0.0259500 -0.0075600 0.0000360 -0.0000047 -0.0098200 -0.0094000 
Other co-
morbidity (yes) 
-0.0577600 -0.0007200 -0.0030100 -0.0022900 0.0000090 -0.0000300 -0.0236700 -0.0142700 -0.0083700 -0.0026600 -0.0671500 0.4802000 0.0074010 -0.0846500 -0.0603000 0.0414000 0.0000470 -0.0000100 -0.0198200 -0.0053300 
Current smoker -0.5141000 0.0017910 0.0053290 -0.0007200 0.0001010 -0.0000200 0.0013510 -0.0086700 -0.0476100 0.0068350 -0.0078800 0.0074010 0.4268000 -0.0098900 0.0412400 -0.0731900 -0.0000900 -0.0001100 0.0287200 0.0142000 
Female -0.5780000 0.0030710 -0.0023200 0.0089510 -0.0000500 0.0001240 0.0255100 0.0102300 0.0184900 0.0040260 0.0578000 -0.0846500 -0.0098900 0.4454000 0.0031690 -0.0268300 0.0000790 -0.0000089 0.0309700 -0.0018100 
High BMI  -0.1809000 0.0000340 0.0034100 0.0074520 0.0001470 -0.0000700 -0.0169700 -0.0084200 0.0096160 0.0025420 -0.0259500 -0.0603000 0.0412400 0.0031690 0.5633000 0.1077000 0.0002430 -0.0003000 -0.0127800 0.0171200 
Low BMI  -0.4960000 0.0038210 0.0032640 -0.0073100 0.0000840 0.0000670 -0.0134600 -0.0173700 -0.0059300 0.0021350 -0.0075600 0.0414000 -0.0731900 -0.0268300 0.1077000 0.7943000 -0.0000200 0.0002810 0.0139900 -0.0196400 
Baseline 6MWD -0.0030800 -0.0000600 -0.0000100 -0.0000300 -0.0000044 -0.0000002 -0.0000500 -0.0000300 0.0000073 0.0000055 0.0000360 0.0000470 -0.0000900 0.0000790 0.0002430 -0.0000200 0.0000110 0.0000004 0.0005000 0.0000630 
Fibrinogen -0.0038600 0.0000190 -0.0000200 -0.0000400 0.0000003 0.0000003 -0.0000300 -0.0000098 -0.0000500 -0.0000100 -0.0000047 -0.0000100 -0.0001100 -0.0000089 -0.0003000 0.0002810 0.0000004 0.0000092 -0.0000500 -0.0000700 
Baseline mMRC -0.6183000 0.0047310 -0.0017700 -0.0011700 0.0001740 0.0000560 -0.0476200 -0.0270000 -0.0089200 0.0020590 -0.0098200 -0.0198200 0.0287200 0.0309700 -0.0127800 0.0139900 0.0005000 -0.0000500 0.4499000 -0.0329000 
Prior exac. -0.3254000 0.0015730 -0.0228200 -0.0165800 0.0000680 0.0000360 -0.0074400 -0.0082000 -0.0108000 0.0021180 -0.0094000 -0.0053300 0.0142000 -0.0018100 0.0171200 -0.0196400 0.0000630 -0.0000700 -0.0329000 0.3934000 
BMI, body-mass index; CVD, cardiovascular disease; FEV1, forced expiratory volume in one second; mMRC, modified Medical Research Council; SGRQ, St George’s Respiratory Questionnaire; 6MWD, six-minute walk test distance. 
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Moderate exac. 0.0037852 -0.0009536 -0.0000004 0.0000214 -0.0004498 -0.0005837 -0.0003527 0.0000310 0.0002794 -0.0003335 0.0005495 -0.0006595 0.0004177 0.0001522 -0.0000025 -0.0004116 -0.0000333 
Severe exac. -0.0009536 0.0092594 0.0000064 0.0000494 0.0000921 0.0005358 0.0001759 -0.0000507 0.0008694 -0.0006272 0.0002450 0.0001818 0.0011632 -0.0001085 -0.0000010 0.0017171 -0.0000537 
6MWD 
augmented 
-0.0000004 0.0000064 0.0000006 -0.0000013 -0.0000227 -0.0000196 0.0000040 0.0000016 0.0000096 0.0000044 -0.0000004 0.0000186 0.0000240 -0.0000014 0.0000000 0.0000267 0.0000011 
FEV1 % 
predicted 










-0.0005837 0.0005358 -0.0000196 0.0001542 0.0825069 0.1007333 -0.0028780 -0.0001023 -0.0003788 -0.0013102 -0.0004381 -0.0004569 -0.0022597 -0.0045485 -0.0000013 -0.0020880 -0.0002572 
Symptom  
most days 
-0.0003527 0.0001759 0.0000040 -0.0000687 -0.0052756 -0.0028780 0.0254577 -0.0000664 0.0013234 -0.0013912 -0.0052671 0.0022173 0.0025811 -0.0001866 -0.0000048 0.0009641 -0.0001546 
Age 0.0000310 -0.0000507 0.0000016 -0.0000113 -0.0000633 -0.0001023 -0.0000664 0.0001572 -0.0001580 -0.0001465 0.0004001 0.0002588 0.0002198 0.0000321 -0.0000006 -0.0001185 0.0000093 
CVD co-
morbidity (yes) 
0.0002794 0.0008694 0.0000096 -0.0000885 -0.0004006 -0.0003788 0.0013234 -0.0001580 0.0232562 -0.0029193 -0.0000084 0.0036315 -0.0009330 0.0000515 -0.0000017 -0.0001970 -0.0000555 
Other co-
morbidity (yes) 
-0.0003335 -0.0006272 0.0000044 -0.0000744 -0.0005589 -0.0013102 -0.0013912 -0.0001465 -0.0029193 0.0333684 0.0009624 -0.0043212 -0.0036254 0.0018382 -0.0000008 -0.0003483 -0.0000359 
Current 
smoker 
0.0005495 0.0002450 -0.0000004 -0.0000956 0.0001624 -0.0004381 -0.0052671 0.0004001 -0.0000084 0.0009624 0.0270082 0.0009413 0.0022005 -0.0034808 -0.0000024 0.0024520 -0.0000037 
Female -0.0006595 0.0001818 0.0000186 -0.0002339 -0.0019112 -0.0004569 0.0022173 0.0002588 0.0036315 -0.0043212 0.0009413 0.0294044 0.0015925 -0.0043518 -0.0000067 0.0000986 0.0000113 
High BMI 
category  
0.0004177 0.0011632 0.0000240 -0.0002044 -0.0024726 -0.0022597 0.0025811 0.0002198 -0.0009330 -0.0036254 0.0022005 0.0015925 0.0348637 0.0080983 -0.0000099 0.0000580 -0.0000084 
Low BMI 
category 
0.0001522 -0.0001085 -0.0000014 0.0001396 -0.0023400 -0.0045485 -0.0001866 0.0000321 0.0000515 0.0018382 -0.0034808 -0.0043518 0.0080983 0.0397087 0.0000151 0.0017781 -0.0000455 
Fibrinogen -0.0000025 -0.0000010 0.0000000 0.0000005 -0.0000013 -0.0000013 -0.0000048 -0.0000006 -0.0000017 -0.0000008 -0.0000024 -0.0000067 -0.0000099 0.0000151 0.0000004 -0.0000027 -0.0000002 
Baseline 
mMRC 
-0.0004116 0.0017171 0.0000267 0.0001059 -0.0029721 -0.0020880 0.0009641 -0.0001185 -0.0001970 -0.0003483 0.0024520 0.0000986 0.0000580 0.0017781 -0.0000027 0.0360665 -0.0003247 
Baseline 
SGRQ 
-0.0000333 -0.0000537 0.0000011 0.0000023 -0.0004801 -0.0002572 -0.0001546 0.0000093 -0.0000555 -0.0000359 -0.0000037 0.0000113 -0.0000084 -0.0000455 -0.0000002 -0.0003247 0.0000286 




Table A17 Covariance matrix for survival (fixed effects) 








































Intercept 0.7445900 -0.0014810 -0.0008500 -0.0001700 -0.0003460 -0.0330840 -0.0302390 0.0066220 -0.0070450 -0.0008520 -0.0075890 -0.0209270 -0.0064020 -0.0105250 -0.0171820 -0.0001370 -0.0048730 -0.0010570 0.0148100 
Moderate 
exac. 
-0.0014810 0.0022350 -0.0011570 -0.0000003 0.0000127 -0.0002340 -0.0003090 -0.0002830 0.0000188 0.0001320 -0.0002220 0.0003450 -0.0003680 0.0002110 0.0001830 -0.0000012 -0.0002190 -0.0000185 -0.0000354 
Severe exac. -0.0008500 -0.0011570 0.0112520 0.0000042 0.0000289 0.0001590 0.0003350 0.0006050 -0.0000193 0.0004530 -0.0003470 0.0000299 0.0001660 0.0006880 -0.0005650 -0.0000017 0.0003520 -0.0000380 0.0000219 
6MWD 
augmented 
-0.0001700 -0.0000003 0.0000042 0.0000004 -0.0000006 -0.0000131 -0.0000102 0.0000026 0.0000005 0.0000025 0.0000027 -0.0000025 0.0000134 0.0000131 -0.0000033 0.0000000 0.0000151 0.0000007 0.0000088 
FEV1 % 
predicted 




most days  





-0.0302390 -0.0003090 0.0003350 -0.0000102 0.0001090 0.0482970 0.0588700 -0.0018030 -0.0000691 -0.0002550 -0.0008880 -0.0003900 -0.0003880 -0.0015950 -0.0030520 -0.0000017 -0.0012800 -0.0001460 0.0003330 
Symptom  
most days 
0.0066220 -0.0002830 0.0006050 0.0000026 -0.0000321 -0.0031610 -0.0018030 0.0149720 -0.0000611 0.0008050 -0.0010320 -0.0029990 0.0013300 0.0015030 -0.0002630 -0.0000031 0.0007990 -0.0000946 0.0002410 








-0.0075890 -0.0002220 -0.0003470 0.0000027 -0.0000459 -0.0002790 -0.0008880 -0.0010320 -0.0000547 -0.0018170 0.0199030 0.0007110 -0.0026670 -0.0020980 0.0011480 0.0000004 -0.0001750 -0.0000154 -0.0002970 
Current 
smoker 
-0.0209270 0.0003450 0.0000299 -0.0000025 -0.0000618 -0.0000737 -0.0003900 -0.0029990 0.0002680 -0.0000540 0.0007110 0.0158000 0.0006350 0.0011010 -0.0017360 -0.0000008 0.0011000 0.0000050 -0.0005780 
Female -0.0064020 -0.0003680 0.0001660 0.0000134 -0.0001240 -0.0011880 -0.0003880 0.0013300 0.0001090 0.0018910 -0.0026670 0.0006350 0.0172750 0.0008540 -0.0027290 -0.0000037 0.0002310 0.0000013 0.0006020 
High BMI 
category  
-0.0105250 0.0002110 0.0006880 0.0000131 -0.0001160 -0.0016420 -0.0015950 0.0015030 0.0001400 -0.0004820 -0.0020980 0.0011010 0.0008540 0.0202720 0.0050270 -0.0000049 -0.0002190 0.0000018 -0.0001300 
Low BMI 
category 
-0.0171820 0.0001830 -0.0005650 -0.0000033 0.0000624 -0.0015430 -0.0030520 -0.0002630 0.0000684 0.0006670 0.0011480 -0.0017360 -0.0027290 0.0050270 0.0237090 0.0000106 0.0009540 -0.0000204 -0.0012160 
Fibrinogen -0.0001370 -0.0000012 -0.0000017 0.0000000 0.0000002 -0.0000007 -0.0000017 -0.0000031 0.0000000 0.0000006 0.0000004 -0.0000008 -0.0000037 -0.0000049 0.0000106 0.0000002 -0.0000014 -0.0000001 -0.0000049 
Baseline 
mMRC 
-0.0048730 -0.0002190 0.0003520 0.0000151 0.0000622 -0.0016600 -0.0012800 0.0007990 -0.0000763 0.0000501 -0.0001750 0.0011000 0.0002310 -0.0002190 0.0009540 -0.0000014 0.0214270 -0.0001930 -0.0001810 
Baseline 
SGRQ 
-0.0010570 -0.0000185 -0.0000380 0.0000007 0.0000013 -0.0002810 -0.0001460 -0.0000946 0.0000056 -0.0000384 -0.0000154 0.0000050 0.0000013 0.0000018 -0.0000204 -0.0000001 -0.0001930 0.0000169 -0.0000011 
Scale  0.0148100 -0.0000354 0.0000219 0.0000088 0.0000333 -0.0000582 0.0003330 0.0002410 -0.0001460 -0.0009500 -0.0002970 -0.0005780 0.0006020 -0.0001300 -0.0012160 -0.0000049 -0.0001810 -0.0000011 0.0028390 
BMI, body-mass index; CVD, cardiovascular disease; FEV1, forced expiratory volume in one second; mMRC, modified Medical Research Council; SGRQ, St George’s Respiratory Questionnaire; 6MWD, six-minute walk test distance. 
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Table A18 Covariance matrix (probability of hospitalization) 






























mMRC SGRQ Prior exac. 
Intercept 0.2039000 0.0002030 -0.0005300 0.0023080 -0.0004400 -0.0159600 -0.0186700 0.0009240 -0.0017600 0.0033040 -0.0025900 -0.0109800 -0.0075100 -0.0015200 -0.0029600 -0.0245100 -0.0003600 -0.0036800 
Time (log 
years) 
0.0002030 0.0002990 0.0000290 -0.0000600 -0.0000028 0.0004000 0.0002300 0.0000300 0.0000046 0.0000028 -0.0000400 -0.0000100 -0.0000600 0.0000200 -0.0000200 -0.0000800 -0.0000010 -0.0000500 
Moderate 
exac. count 
-0.0005300 0.0000290 0.0002550 -0.0001100 0.0000041 -0.0002700 -0.0000900 -0.0001000 0.0000001 0.0000400 -0.0002500 0.0000940 -0.0002100 -0.0000300 -0.0001200 0.0001930 0.0000026 -0.0000800 
Severe exac. 
count 
0.0023080 -0.0000600 -0.0001100 0.0060100 -0.0000082 0.0001470 -0.0000400 0.0000360 -0.0000500 -0.0009400 -0.0002800 -0.0001900 -0.0002100 -0.0010800 -0.0001100 -0.0002200 -0.0000100 -0.0000500 
FEV1 % 
predicted 









-0.0186700 0.0002300 -0.0000900 -0.0000400 0.0000290 0.0199600 0.0227900 0.0001990 0.0000170 0.0000960 -0.0002500 -0.0007000 -0.0001100 0.0001270 0.0001760 -0.0008100 -0.0000300 -0.0002000 
Cough and 
sputum 
0.0009240 0.0000300 -0.0001000 0.0000360 -0.0000200 -0.0020000 0.0001990 0.0080500 0.0000040 0.0005250 -0.0005300 -0.0015800 0.0004540 0.0004970 -0.0001600 0.0000380 -0.0000400 -0.0001800 
Age -0.0017600 0.0000046 0.0000001 -0.0000500 -0.0000014 0.0000019 0.0000170 0.0000040 0.0000280 -0.0000500 -0.0000400 0.0001310 0.0000430 0.0000300 -0.0000100 -0.0000700 0.0000015 -0.0000029 
CVD co-
morbidity 
0.0033040 0.0000028 0.0000400 -0.0009400 -0.0000300 -0.0002800 0.0000960 0.0005250 -0.0000500 0.0106800 0.0003050 -0.0004100 0.0003910 -0.0001000 -0.0004300 0.0002370 -0.0000200 0.0000180 
Other co-
morbidity 
-0.0025900 -0.0000400 -0.0002500 -0.0002800 -0.0000200 -0.0009300 -0.0002500 -0.0005300 -0.0000400 0.0003050 0.0092630 0.0004850 -0.0011000 -0.0006600 0.0010010 0.0000300 0.0000076 0.0002170 
Current 
smoker 
-0.0109800 -0.0000100 0.0000940 -0.0001900 -0.0000100 -0.0000900 -0.0007000 -0.0015800 0.0001310 -0.0004100 0.0004850 0.0078500 -0.0004000 0.0002180 -0.0010600 -0.0000700 0.0000130 -0.0001500 
Sex -0.0075100 -0.0000600 -0.0002100 -0.0002100 0.0000750 -0.0002400 -0.0001100 0.0004540 0.0000430 0.0003910 -0.0011000 -0.0004000 0.0106100 -0.0010200 0.0000130 -0.0000700 0.0000076 0.0004060 
BMI (high 
vs normal) 
-0.0015200 0.0000200 -0.0000300 -0.0010800 -0.0000200 0.0004440 0.0001270 0.0004970 0.0000300 -0.0001000 -0.0006600 0.0002180 -0.0010200 0.0175900 0.0024620 -0.0007200 -0.0000200 0.0002700 
BMI (low vs 
normal) 
-0.0029600 -0.0000200 -0.0001200 -0.0001100 0.0000590 0.0004650 0.0001760 -0.0001600 -0.0000100 -0.0004300 0.0010010 -0.0010600 0.0000130 0.0024620 0.0098460 -0.0004100 -0.0000200 -0.0006300 
mMRC -0.0245100 -0.0000800 0.0001930 -0.0002200 0.0000280 -0.0009300 -0.0008100 0.0000380 -0.0000700 0.0002370 0.0000300 -0.0000700 -0.0000700 -0.0007200 -0.0004100 0.0351500 -0.0001000 0.0004680 
SGRQ -0.0003600 -0.0000010 0.0000026 -0.0000100 0.0000010 -0.0000900 -0.0000300 -0.0000400 0.0000015 -0.0000200 0.0000076 0.0000130 0.0000076 -0.0000200 -0.0000200 -0.0001000 0.0000076 -0.0000400 
Prior exac. -0.0036800 -0.0000500 -0.0000800 -0.0000500 0.0000044 0.0000150 -0.0002000 -0.0001800 -0.0000029 0.0000180 0.0002170 -0.0001500 0.0004060 0.0002700 -0.0006300 0.0004680 -0.0000400 0.0080900 




































mMRC SGRQ Prior exac. 
Intercept 0.1091600 -0.0000820 0.0000461 0.0002187 -0.0002020 -0.0130400 -0.0145400 -0.0001030 -0.0009190 0.0012200 -0.0025030 -0.0041960 -0.0035270 -0.0013090 -0.0024520 -0.0109700 -0.0001730 -0.0022330 
Time (log 
years) 
-0.0000820 0.0001450 0.0000150 0.0000032 0.0000011 0.0001536 0.0001225 0.0000205 0.0000010 -0.0000360 -0.0000120 -0.0000310 0.0000206 -0.0000110 0.0000445 0.0000436 -0.0000001 -0.0000110 
Moderate 
exac. count 
0.0000461 0.0000150 0.0000646 -0.0000500 -0.0000007 -0.0001290 -0.0001240 0.0000168 0.0000005 0.0000798 -0.0000420 0.0000386 -0.0000640 -0.0000810 -0.0000140 -0.0000220 0.0000006 0.0000250 
Severe exac. 
count 
0.0002187 0.0000032 -0.0000500 0.0001072 0.0000045 0.0001159 0.0001277 0.0000593 -0.0000079 -0.0000610 -0.0000430 -0.0000260 0.0001778 -0.0001140 -0.0000590 0.0000752 -0.0000023 -0.0000036 
FEV1 % 
predicted 









-0.0145400 0.0001225 -0.0001240 0.0001277 0.0000093 0.0120700 0.0136900 -0.0002080 0.0000368 0.0003118 0.0001811 -0.0003560 0.0000320 0.0003139 0.0007298 -0.0000550 -0.0000019 -0.0001140 
Cough and 
sputum 
-0.0001030 0.0000205 0.0000168 0.0000593 -0.0000093 -0.0013250 -0.0002080 0.0037650 0.0000025 -0.0000470 -0.0001200 -0.0005950 0.0001126 0.0005259 -0.0001040 0.0004401 -0.0000180 -0.0001050 
Age -0.0009190 0.0000010 0.0000005 -0.0000079 -0.0000007 0.0000259 0.0000368 0.0000025 0.0000140 -0.0000300 -0.0000130 0.0000539 0.0000165 0.0000246 -0.0000005 -0.0000340 0.0000005 0.0000018 
CVD co-
morbidity 
0.0012200 -0.0000360 0.0000798 -0.0000610 -0.0000055 0.0003144 0.0003118 -0.0000470 -0.0000300 0.0041730 0.0002184 -0.0000410 -0.0000030 0.0000479 0.0000171 -0.0001600 -0.0000099 0.0000765 
Other co-
morbidity 
-0.0025030 -0.0000120 -0.0000420 -0.0000430 -0.0000061 0.0000296 0.0001811 -0.0001200 -0.0000130 0.0002184 0.0047760 0.0004087 -0.0006140 -0.0001980 0.0002566 0.0001125 -0.0000048 0.0000929 
Current 
smoker 
-0.0041960 -0.0000310 0.0000386 -0.0000260 -0.0000100 -0.0003540 -0.0003560 -0.0005950 0.0000539 -0.0000410 0.0004087 0.0036990 -0.0004520 0.0000613 -0.0003120 -0.0000590 -0.0000009 0.0000977 
Sex -0.0035270 0.0000206 -0.0000640 0.0001778 0.0000374 -0.0000720 0.0000320 0.0001126 0.0000165 -0.0000030 -0.0006140 -0.0004520 0.0055080 -0.0003620 -0.0000440 0.0000696 0.0000041 -0.0000350 
BMI (high 
vs normal) 
-0.0013090 -0.0000110 -0.0000810 -0.0001140 -0.0000170 -0.0001480 0.0003139 0.0005259 0.0000246 0.0000479 -0.0001980 0.0000613 -0.0003620 0.0081920 0.0014770 -0.0006580 -0.0000120 0.0007783 
BMI (low vs 
normal) 
-0.0024520 0.0000445 -0.0000140 -0.0000590 0.0000283 0.0010140 0.0007298 -0.0001040 -0.0000005 0.0000171 0.0002566 -0.0003120 -0.0000440 0.0014770 0.0042600 -0.0003420 -0.0000051 -0.0002560 
mMRC -0.0109700 0.0000436 -0.0000220 0.0000752 0.0000088 -0.0001980 -0.0000550 0.0004401 -0.0000340 -0.0001600 0.0001125 -0.0000590 0.0000696 -0.0006580 -0.0003420 0.0163000 -0.0000440 -0.0001750 
SGRQ -0.0001730 -0.0000001 0.0000006 -0.0000023 0.0000005 -0.0000280 -0.0000019 -0.0000180 0.0000005 -0.0000099 -0.0000048 -0.0000009 0.0000041 -0.0000120 -0.0000051 -0.0000440 0.0000037 -0.0000180 
Prior exac. -0.0022330 -0.0000110 0.0000250 -0.0000036 0.0000068 0.0001809 -0.0001140 -0.0001050 0.0000018 0.0000765 0.0000929 0.0000977 -0.0000350 0.0007783 -0.0002560 -0.0001750 -0.0000180 0.0039300 




Table A20 Covariance matrix (intensive care unit)  






























mMRC SGRQ Prior exac. 
Intercept 1.1393100 -0.0016900 0.0012370 0.0034540 -0.0023400 -0.1097300 -0.1224800 -0.0000670 -0.0106000 0.0081730 -0.0461400 -0.0618700 -0.0387200 -0.0248300 -0.0275800 -0.0460100 -0.0020340 -0.0157500 
Time (log 
years) 
-0.0016900 0.0020300 0.0001408 0.0001762 0.0000177 0.0015040 0.0013500 0.0001955 0.0000196 -0.0005020 -0.0003470 -0.0004870 0.0000077 0.0001811 0.0004686 0.0001856 0.0000001 -0.0001770 
Moderate 
exac. count 
0.0012370 0.0001408 0.0004546 -0.0004010 -0.0000120 -0.0011830 -0.0008580 -0.0001970 -0.0000110 0.0008472 -0.0004340 0.0004293 -0.0010230 -0.0003530 -0.0001970 -0.0001440 0.0000075 0.0000856 
Severe exac. 
count 
0.0034540 0.0001762 -0.0004010 0.0010000 0.0000509 0.0002784 0.0008151 0.0012930 -0.0000870 -0.0002570 -0.0002940 -0.0001340 0.0020560 -0.0017940 -0.0005790 0.0003371 -0.0000290 0.0002909 
FEV1 % 
predicted 









-0.1224800 0.0013500 -0.0008580 0.0008151 0.0001538 0.0936600 0.1092300 -0.0009320 0.0003995 0.0017940 0.0014470 -0.0028600 0.0000523 0.0052300 0.0076350 -0.0009980 -0.0000260 -0.0005070 
Cough and 
sputum 
-0.0000670 0.0001955 -0.0001970 0.0012930 -0.0001040 -0.0145100 -0.0009320 0.0453800 0.0000243 -0.0004220 -0.0020870 -0.0067460 0.0010150 0.0076630 -0.0007750 0.0045430 -0.0002170 -0.0013030 
Age -0.0106000 0.0000196 -0.0000110 -0.0000870 -0.0000087 0.0003501 0.0003995 0.0000243 0.0001619 -0.0002940 -0.0001880 0.0007178 0.0002506 0.0003265 -0.0000086 -0.0002500 0.0000058 -0.0000270 
CVD co-
morbidity 
0.0081730 -0.0005020 0.0008472 -0.0002570 -0.0000410 0.0008511 0.0017940 -0.0004220 -0.0002940 0.0404600 -0.0007180 -0.0009620 -0.0004050 -0.0005300 -0.0009670 -0.0008500 -0.0000850 0.0014820 
Other co-
morbidity 
-0.0461400 -0.0003470 -0.0004340 -0.0002940 -0.0000660 -0.0007060 0.0014470 -0.0020870 -0.0001880 -0.0007180 0.0743400 0.0033810 -0.0063760 -0.0034010 0.0018260 0.0012870 -0.0000220 0.0007403 
Current 
smoker 
-0.0618700 -0.0004870 0.0004293 -0.0001340 -0.0000880 -0.0034860 -0.0028600 -0.0067460 0.0007178 -0.0009620 0.0033810 0.0421300 -0.0038860 -0.0015410 -0.0038170 -0.0004660 0.0000250 0.0005934 
Sex -0.0387200 0.0000077 -0.0010230 0.0020560 0.0003959 -0.0000880 0.0000523 0.0010150 0.0002506 -0.0004050 -0.0063760 -0.0038860 0.0922400 -0.0024060 -0.0008090 -0.0006120 0.0000463 -0.0014900 
BMI (high 
vs normal) 
-0.0248300 0.0001811 -0.0003530 -0.0017940 -0.0001080 -0.0005230 0.0052300 0.0076630 0.0003265 -0.0005300 -0.0034010 -0.0015410 -0.0024060 0.0726300 0.0202100 -0.0055540 -0.0001460 0.0092990 
BMI (low vs 
normal) 
-0.0275800 0.0004686 -0.0001970 -0.0005790 0.0003339 0.0133400 0.0076350 -0.0007750 -0.0000086 -0.0009670 0.0018260 -0.0038170 -0.0008090 0.0202100 0.0549000 -0.0022130 -0.0001060 -0.0040450 
mMRC -0.0460100 0.0001856 -0.0001440 0.0003371 0.0001027 -0.0030620 -0.0009980 0.0045430 -0.0002500 -0.0008500 0.0012870 -0.0004660 -0.0006120 -0.0055540 -0.0022130 0.0994600 -0.0005240 -0.0015840 
SGRQ -0.0020340 0.0000001 0.0000075 -0.0000290 0.0000061 -0.0003430 -0.0000260 -0.0002170 0.0000058 -0.0000850 -0.0000220 0.0000250 0.0000463 -0.0001460 -0.0001060 -0.0005240 0.0000434 -0.0002010 
Prior exac. -0.0157500 -0.0001770 0.0000856 0.0002909 0.0000707 0.0040200 -0.0005070 -0.0013030 -0.0000270 0.0014820 0.0007403 0.0005934 -0.0014900 0.0092990 -0.0040450 -0.0015840 -0.0002010 0.0394000 




Table A21 Covariance matrix (emergency room visits)  






























mMRC SGRQ Prior exac. 
Intercept 0.8437400 0.0005724 0.0000682 0.0032500 -0.0017690 -0.0885400 -0.1026900 0.0031460 -0.0077180 0.0086530 -0.0149000 -0.0375100 -0.0301700 -0.0083870 -0.0188900 -0.0500700 -0.0013680 -0.0165400 
Time (log 
years) 
0.0005724 0.0010800 0.0000125 0.0000641 0.0000018 0.0010690 0.0006949 0.0000284 0.0000087 -0.0000710 -0.0000640 -0.0001980 -0.0000140 0.0000760 0.0001486 -0.0000460 0.0000024 -0.0000390 
Moderate 
exac. count 
0.0000682 0.0000125 0.0002859 -0.0003060 -0.0000032 -0.0005830 -0.0003290 -0.0001410 -0.0000003 0.0001140 -0.0005290 0.0001047 -0.0006240 -0.0002270 -0.0000920 0.0001730 0.0000022 -0.0000590 
Severe exac. 
count 
0.0032500 0.0000641 -0.0003060 0.0010920 0.0000253 0.0002766 0.0000574 0.0006597 -0.0000570 0.0002649 -0.0000190 0.0000576 0.0013730 -0.0015890 -0.0005120 -0.0002840 -0.0000150 0.0001079 
FEV1 % 
predicted 









-0.1026900 0.0006949 -0.0003290 0.0000574 0.0001145 0.1028400 0.1134000 -0.0010350 0.0001238 -0.0005190 -0.0005920 -0.0018950 -0.0006020 0.0020650 0.0029690 -0.0009330 -0.0001120 -0.0019200 
Cough and 
sputum 
0.0031460 0.0000284 -0.0001410 0.0006597 -0.0000740 -0.0090920 -0.0010350 0.0302700 -0.0000046 -0.0003810 -0.0012290 -0.0055440 0.0010100 0.0022750 -0.0010140 0.0017620 -0.0001320 -0.0004810 
Age -0.0077180 0.0000087 -0.0000003 -0.0000570 -0.0000053 0.0000150 0.0001238 -0.0000046 0.0001171 -0.0002100 -0.0001830 0.0004841 0.0001939 0.0001421 -0.0000130 -0.0001410 0.0000047 0.0000409 
CVD co-
morbidity 
0.0086530 -0.0000710 0.0001140 0.0002649 -0.0000530 -0.0004160 -0.0005190 -0.0003810 -0.0002100 0.0380100 0.0012460 0.0008099 -0.0004420 0.0011930 -0.0000640 -0.0000470 -0.0000510 0.0006794 
Other co-
morbidity 
-0.0149000 -0.0000640 -0.0005290 -0.0000190 -0.0000320 -0.0024440 -0.0005920 -0.0012290 -0.0001830 0.0012460 0.0404100 0.0022980 -0.0043620 -0.0014670 0.0027620 0.0008016 -0.0000230 0.0010860 
Current 
smoker 
-0.0375100 -0.0001980 0.0001047 0.0000576 -0.0000870 -0.0008110 -0.0018950 -0.0055440 0.0004841 0.0008099 0.0022980 0.0310200 -0.0024680 0.0014060 -0.0034280 0.0000900 -0.0000160 0.0001707 
Sex -0.0301700 -0.0000140 -0.0006240 0.0013730 0.0002893 -0.0013060 -0.0006020 0.0010100 0.0001939 -0.0004420 -0.0043620 -0.0024680 0.0430100 -0.0025490 -0.0005650 -0.0009060 0.0000561 0.0000519 
BMI (high 
vs normal) 
-0.0083870 0.0000760 -0.0002270 -0.0015890 -0.0001200 -0.0000480 0.0020650 0.0022750 0.0001421 0.0011930 -0.0014670 0.0014060 -0.0025490 0.0776600 0.0111700 -0.0032020 -0.0000940 0.0045200 
BMI (low vs 
normal) 
-0.0188900 0.0001486 -0.0000920 -0.0005120 0.0002316 0.0047950 0.0029690 -0.0010140 -0.0000130 -0.0000640 0.0027620 -0.0034280 -0.0005650 0.0111700 0.0346400 -0.0004850 -0.0000450 -0.0019800 
mMRC -0.0500700 -0.0000460 0.0001730 -0.0002840 0.0000600 -0.0025640 -0.0009330 0.0017620 -0.0001410 -0.0000470 0.0008016 0.0000900 -0.0009060 -0.0032020 -0.0004850 0.0805600 -0.0003020 -0.0004560 
SGRQ -0.0013680 0.0000024 0.0000022 -0.0000150 0.0000052 -0.0003520 -0.0001120 -0.0001320 0.0000047 -0.0000510 -0.0000230 -0.0000160 0.0000561 -0.0000940 -0.0000450 -0.0003020 0.0000294 -0.0001150 
Prior exac. -0.0165400 -0.0000390 -0.0000590 0.0001079 0.0000507 -0.0003250 -0.0019200 -0.0004810 0.0000409 0.0006794 0.0010860 0.0001707 0.0000519 0.0045200 -0.0019800 -0.0004560 -0.0001150 0.0285600 




Table A22 Covariance matrix (days and nights at home)  






























mMRC SGRQ Prior exac. 
Intercept 2.8069600 0.0042910 -0.0028370 0.0104500 -0.0045420 -0.1197100 -0.1612000 0.0111200 -0.0213600 0.0202900 -0.0708200 -0.1012200 -0.0938700 -0.0231900 -0.0413300 -0.6375400 -0.0034670 -0.0985200 
Time (log 
years) 
0.0042910 0.0029070 0.0001068 -0.0000880 -0.0000040 0.0034790 0.0021130 0.0006597 0.0000178 -0.0000870 -0.0001640 -0.0005230 -0.0000770 -0.0004100 0.0001206 0.0000132 -0.0000160 0.0001079 
Moderate 
exac. count 
-0.0028370 0.0001068 0.0012540 -0.0009310 -0.0000020 -0.0018440 -0.0009680 -0.0004530 0.0000265 0.0003873 -0.0014790 0.0004079 -0.0018130 -0.0007520 -0.0005650 0.0009193 0.0000093 -0.0001980 
Severe exac. 
count 
0.0104500 -0.0000880 -0.0009310 0.0062780 0.0000874 0.0021000 0.0009182 0.0010620 -0.0001910 -0.0005110 -0.0006910 0.0001064 0.0031080 -0.0006130 -0.0019520 -0.0006310 -0.0000700 -0.0006130 
FEV1 % 
predicted 









-0.1612000 0.0021130 -0.0009680 0.0009182 0.0002347 0.1607700 0.1853400 -0.0019470 0.0003588 -0.0023290 -0.0008440 -0.0051190 -0.0017550 0.0040100 0.0081660 -0.0022910 -0.0002770 -0.0034500 
Cough and 
sputum 
0.0111200 0.0006597 -0.0004530 0.0010620 -0.0001470 -0.0198800 -0.0019470 0.0780700 -0.0000500 -0.0001810 -0.0022340 -0.0141300 0.0016400 0.0029740 -0.0012240 0.0031790 -0.0003850 -0.0001800 
Age -0.0213600 0.0000178 0.0000265 -0.0001910 -0.0000120 0.0000956 0.0003588 -0.0000500 0.0003168 -0.0005410 -0.0004640 0.0012480 0.0006211 0.0004760 -0.0001470 -0.0003010 0.0000127 0.0000845 
CVD co-
morbidity 
0.0202900 -0.0000870 0.0003873 -0.0005110 -0.0001240 -0.0033810 -0.0023290 -0.0001810 -0.0005410 0.0876800 0.0044070 0.0009843 -0.0009580 0.0017830 0.0000637 0.0021200 -0.0001340 0.0019790 
Other co-
morbidity 
-0.0708200 -0.0001640 -0.0014790 -0.0006910 -0.0000810 -0.0050760 -0.0008440 -0.0022340 -0.0004640 0.0044070 0.1315000 0.0049580 -0.0108300 -0.0052270 0.0097800 0.0030250 -0.0001040 0.0029260 
Current 
smoker 
-0.1012200 -0.0005230 0.0004079 0.0001064 -0.0002000 -0.0042420 -0.0051190 -0.0141300 0.0012480 0.0009843 0.0049580 0.0805600 -0.0070460 0.0044830 -0.0106000 0.0028260 0.0000111 0.0002523 
Sex -0.0938700 -0.0000770 -0.0018130 0.0031080 0.0008312 -0.0041450 -0.0017550 0.0016400 0.0006211 -0.0009580 -0.0108300 -0.0070460 0.1096000 -0.0084730 -0.0001850 -0.0012200 0.0001424 0.0014420 
BMI (high 
vs normal) 
-0.0231900 -0.0004100 -0.0007520 -0.0006130 -0.0003740 0.0004823 0.0040100 0.0029740 0.0004760 0.0017830 -0.0052270 0.0044830 -0.0084730 0.2353300 0.0237900 -0.0106200 -0.0001640 0.0049220 
BMI (low vs 
normal) 
-0.0413300 0.0001206 -0.0005650 -0.0019520 0.0005766 0.0101700 0.0081660 -0.0012240 -0.0001470 0.0000637 0.0097800 -0.0106000 -0.0001850 0.0237900 0.0933600 -0.0013580 -0.0001330 -0.0025490 
mMRC -0.6375400 0.0000132 0.0009193 -0.0006310 0.0002149 -0.0061720 -0.0022910 0.0031790 -0.0003010 0.0021200 0.0030250 0.0028260 -0.0012200 -0.0106200 -0.0013580 0.7060700 -0.0008210 0.0001734 
SGRQ -0.0034670 -0.0000160 0.0000093 -0.0000700 0.0000112 -0.0008820 -0.0002770 -0.0003850 0.0000127 -0.0001340 -0.0001040 0.0000111 0.0001424 -0.0001640 -0.0001330 -0.0008210 0.0000739 -0.0003290 
Prior exac. -0.0985200 0.0001079 -0.0001980 -0.0006130 0.0001635 -0.0002390 -0.0034500 -0.0001800 0.0000845 0.0019790 0.0029260 0.0002523 0.0014420 0.0049220 -0.0025490 0.0001734 -0.0003290 0.1233000 
BMI, body-mass index; CVD, cardiovascular disease; FEV1, forced expiratory volume in one second; mMRC, modified Medical Research Council; SGRQ, St George’s Respiratory Questionnaire 
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mMRC SGRQ Prior exac. 
Intercept 0.1587500 0.0001214 0.0000996 0.0006582 -0.0003490 -0.0258700 -0.0284300 0.0008488 -0.0012750 0.0008523 -0.0049280 -0.0068270 -0.0058710 -0.0008890 -0.0035210 -0.0122200 -0.0002420 -0.0031080 
Time (log 
years) 
0.0001214 0.0002103 0.0000052 -0.0000360 0.0000000 0.0002090 0.0001219 0.0000162 0.0000011 0.0000050 -0.0000030 -0.0000240 -0.0000110 -0.0000200 0.0000070 0.0000035 0.0000002 0.0000018 
Moderate 
exac. count 
0.0000996 0.0000052 0.0000403 -0.0000590 -0.0000003 -0.0000600 -0.0000330 -0.0000140 -0.0000010 0.0000020 -0.0000960 0.0000161 -0.0001100 -0.0000480 -0.0000110 0.0000269 -0.0000004 -0.0000220 
Severe exac. 
count 
0.0006582 -0.0000360 -0.0000590 0.0007045 0.0000043 -0.0000680 -0.0000300 -0.0000140 -0.0000130 0.0000004 -0.0000210 -0.0000250 0.0002469 -0.0000260 -0.0001040 -0.0000450 -0.0000024 -0.0000410 
FEV1 % 
predicted 









-0.0284300 0.0001219 -0.0000330 -0.0000300 0.0000272 0.0293000 0.0315300 -0.0002450 0.0000066 -0.0001020 -0.0002450 -0.0004120 -0.0001360 0.0002080 0.0004469 -0.0002120 -0.0000190 -0.0002860 
Cough and 
sputum 
0.0008488 0.0000162 -0.0000140 -0.0000140 -0.0000120 -0.0018130 -0.0002450 0.0057060 -0.0000078 0.0000029 -0.0002490 -0.0011720 0.0001823 0.0000673 -0.0001740 0.0003901 -0.0000250 -0.0000420 
Age -0.0012750 0.0000011 -0.0000010 -0.0000130 -0.0000006 -0.0000079 0.0000066 -0.0000078 0.0000195 -0.0000280 -0.0000300 0.0000911 0.0000331 0.0000290 0.0000002 -0.0000190 0.0000010 0.0000095 
CVD co-
morbidity 
0.0008523 0.0000050 0.0000020 0.0000004 -0.0000070 -0.0001500 -0.0001020 0.0000029 -0.0000280 0.0071900 0.0001539 0.0001192 0.0000166 0.0002332 0.0000239 -0.0001690 -0.0000053 0.0001453 
Other co-
morbidity 
-0.0049280 -0.0000030 -0.0000960 -0.0000210 -0.0000048 -0.0006360 -0.0002450 -0.0002490 -0.0000300 0.0001539 0.0098630 0.0004256 -0.0007850 -0.0004940 0.0005407 0.0001252 -0.0000074 0.0002297 
Current 
smoker 
-0.0068270 -0.0000240 0.0000161 -0.0000250 -0.0000160 -0.0000410 -0.0004120 -0.0011720 0.0000911 0.0001192 0.0004256 0.0057430 -0.0004020 0.0003934 -0.0006680 -0.0000170 -0.0000038 0.0000165 
Sex -0.0058710 -0.0000110 -0.0001100 0.0002469 0.0000608 -0.0002130 -0.0001360 0.0001823 0.0000331 0.0000166 -0.0007850 -0.0004020 0.0062980 -0.0005500 -0.0000880 -0.0000950 0.0000070 -0.0001050 
BMI (high 
vs normal) 
-0.0008890 -0.0000200 -0.0000480 -0.0000260 -0.0000250 0.0002069 0.0002080 0.0000673 0.0000290 0.0002332 -0.0004940 0.0003934 -0.0005500 0.0092850 0.0016900 -0.0008750 -0.0000120 0.0001457 
BMI (low vs 
normal) 
-0.0035210 0.0000070 -0.0000110 -0.0001040 0.0000395 0.0005667 0.0004469 -0.0001740 0.0000002 0.0000239 0.0005407 -0.0006680 -0.0000880 0.0016900 0.0091780 0.0000211 -0.0000071 -0.0002710 
mMRC -0.0122200 0.0000035 0.0000269 -0.0000450 0.0000130 -0.0006370 -0.0002120 0.0003901 -0.0000190 -0.0001690 0.0001252 -0.0000170 -0.0000950 -0.0008750 0.0000211 0.0174500 -0.0000570 -0.0000620 
SGRQ -0.0002420 0.0000002 -0.0000004 -0.0000024 0.0000006 -0.0000690 -0.0000190 -0.0000250 0.0000010 -0.0000053 -0.0000074 -0.0000038 0.0000070 -0.0000120 -0.0000071 -0.0000570 0.0000056 -0.0000250 
Prior exac. -0.0031080 0.0000018 -0.0000220 -0.0000410 0.0000079 -0.0000410 -0.0002860 -0.0000420 0.0000095 0.0001453 0.0002297 0.0000165 -0.0001050 0.0001457 -0.0002710 -0.0000620 -0.0000250 0.0054700 
BMI, body-mass index; CVD, cardiovascular disease; FEV1, forced expiratory volume in one second; mMRC, modified Medical Research Council; SGRQ, St George’s Respiratory Questionnaire 
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Table A24 Covariance matrix (outpatient visits)  






























mMRC SGRQ Prior exac. 
Intercept 0.3999300 0.0005560 -0.0001510 0.0021260 -0.0008500 -0.0286500 -0.0352200 0.0020600 -0.0035210 0.0037140 -0.0065340 -0.0185300 -0.0157100 -0.0041190 -0.0084200 -0.0442000 -0.0006750 -0.0084160 
Time (log 
years) 
0.0005560 0.0005441 0.0000167 -0.0000520 -0.0000005 0.0006241 0.0003688 0.0001159 0.0000041 0.0000054 -0.0000270 -0.0000710 -0.0000250 -0.0000580 0.0000107 -0.0000350 -0.0000017 0.0000249 
Moderate 
exac. count 
-0.0001510 0.0000167 0.0001667 -0.0001630 -0.0000001 -0.0002600 -0.0001170 -0.0000370 0.0000008 0.0000396 -0.0002950 0.0000301 -0.0003440 -0.0001130 -0.0000610 0.0001228 -0.0000003 -0.0000300 
Severe exac. 
count 
0.0021260 -0.0000520 -0.0001630 0.0020130 0.0000153 0.0000843 -0.0000090 0.0000641 -0.0000390 -0.0001190 -0.0000630 -0.0000470 0.0006148 -0.0001960 -0.0003260 -0.0001050 -0.0000120 -0.0001990 
FEV1 % 
predicted 









-0.0352200 0.0003688 -0.0001170 -0.0000090 0.0000544 0.0365600 0.0412100 -0.0005600 0.0000485 -0.0006020 -0.0004250 -0.0007950 0.0000053 0.0005747 0.0011650 -0.0005580 -0.0000560 -0.0007840 
Cough and 
sputum 
0.0020600 0.0001159 -0.0000370 0.0000641 -0.0000270 -0.0041980 -0.0005600 0.0147200 -0.0000200 -0.0000390 -0.0005080 -0.0027150 0.0005160 0.0003459 -0.0004750 0.0008070 -0.0000680 -0.0000700 
Age -0.0035210 0.0000041 0.0000008 -0.0000390 -0.0000018 0.0000145 0.0000485 -0.0000200 0.0000536 -0.0000960 -0.0000850 0.0002434 0.0001034 0.0000884 -0.0000140 -0.0000620 0.0000026 0.0000128 
CVD co-
morbidity 
0.0037140 0.0000054 0.0000396 -0.0001190 -0.0000250 -0.0006840 -0.0006020 -0.0000390 -0.0000960 0.0174800 0.0007264 0.0005326 -0.0001570 0.0004505 0.0001809 0.0001613 -0.0000250 0.0005167 
Other co-
morbidity 
-0.0065340 -0.0000270 -0.0002950 -0.0000630 -0.0000130 -0.0013690 -0.0004250 -0.0005080 -0.0000850 0.0007264 0.0185600 0.0010220 -0.0019050 -0.0014010 0.0015620 0.0003520 -0.0000096 0.0005798 
Current 
smoker 
-0.0185300 -0.0000710 0.0000301 -0.0000470 -0.0000400 -0.0004630 -0.0007950 -0.0027150 0.0002434 0.0005326 0.0010220 0.0157300 -0.0010710 0.0010070 -0.0017430 0.0002734 -0.0000035 0.0000644 
Sex -0.0157100 -0.0000250 -0.0003440 0.0006148 0.0001419 -0.0003190 0.0000053 0.0005160 0.0001034 -0.0001570 -0.0019050 -0.0010710 0.0245900 -0.0015380 -0.0000900 -0.0004240 0.0000273 -0.0000270 
BMI (high 
vs normal) 
-0.0041190 -0.0000580 -0.0001130 -0.0001960 -0.0000650 0.0002253 0.0005747 0.0003459 0.0000884 0.0004505 -0.0014010 0.0010070 -0.0015380 0.0388200 0.0044430 -0.0019120 -0.0000280 0.0006994 
BMI (low vs 
normal) 
-0.0084200 0.0000107 -0.0000610 -0.0003260 0.0001086 0.0016450 0.0011650 -0.0004750 -0.0000140 0.0001809 0.0015620 -0.0017430 -0.0000900 0.0044430 0.0184500 0.0000636 -0.0000290 -0.0007420 
mMRC -0.0442000 -0.0000350 0.0001228 -0.0001050 0.0000320 -0.0013330 -0.0005580 0.0008070 -0.0000620 0.0001613 0.0003520 0.0002734 -0.0004240 -0.0019120 0.0000636 0.0587500 -0.0001590 -0.0003410 
SGRQ -0.0006750 -0.0000017 -0.0000003 -0.0000120 0.0000021 -0.0001700 -0.0000560 -0.0000680 0.0000026 -0.0000250 -0.0000096 -0.0000035 0.0000273 -0.0000280 -0.0000290 -0.0001590 0.0000142 -0.0000600 
Prior exac. -0.0084160 0.0000249 -0.0000300 -0.0001990 0.0000231 -0.0003390 -0.0007840 -0.0000700 0.0000128 0.0005167 0.0005798 0.0000644 -0.0000270 0.0006994 -0.0007420 -0.0003410 -0.0000600 0.0151700 
BMI, body-mass index; CVD, cardiovascular disease; FEV1, forced expiratory volume in one second; mMRC, modified Medical Research Council; SGRQ, St George’s Respiratory Questionnaire 
 
